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Abstract 
Erythromycin, a macrolide antibiotic used mainly against gram-positive 
bacteria has been in clinical use since 1952 (1). Previous 
pharmacokinetic data published on this antibiotic have been derived 
predominantly from microbiological assay techniques. However, these 
techniques are relatively imprecise as well as being non-specific and 
extremely tedious to perform. 
A novel high performance liquid chromatographic analysis of 
erythromycin in human serum and urine using U.V. detection at 200 nm 
and/or electrochemical detection using both an amperometric and a 
coulometric electrochemical detector is presented. 
The method involves a solid phase extraction procedure followed by a 
simple phase separation step and chromatography on a reverse phase 
column. In order to select the optimum U.V. detector for this analysis, 
five "state of the art" detectors were compared in terms of their 
signal-to-noise ratios at U.V. wavelengths between 200 and 210 nm. A 
known metabolite des-N-methylerythromycin is readily detectable using 
U.V. detection, whilst another metabolite/degradation product 
anhydroerythromycin is not seen using U.V. detection but is readily 
observable using an electrochemical detector. 
The method has a limit of sensitivity of 0.25 ~g/mL and 1.00 ~g/mL in 
serum and urine respectively (U.V. detection) and is sufficiently 
sensitive to monitor serum and urine concentrations of erythromycin in 
man after administration of a single 500 mg erythromycin stearate 
tablet. 
CHAPTER ONE 
INTRODUCTION 
1.1 PHYSICOCHEMICAL PROPER1IES OF ERYTHROMYCIN 
Erythromycin was discovered by McGuire et al. in 1952 (1) from amongst 
the metabolic products of a strain of Streptomyces erythreus found in a 
soil sample from the Phillipines (1). The major component of the drug 
is erythromycin A, with small amounts of erythromycin Band C being 
present (2). The structures of erythromycin and these two components 
are depicted in Fig. 1.1. Erythromycin is a polyhydroxylactone 
containing two sugars, desosamine, which is a 3-N -dimethyl-aminodeoxy 
sugar, and L-cladinose, which contains no nitrogen and has one methoxy 
group. The aglycone part of the molecule is a 14-member lactone, 
called erythranolide. Both cladinose and desosamine are bound to the 
lactone ring bya B-glycosidic linkage (3). 
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FIGURE 1.2 Postulated synthetic pathways of erythromycin from 
erythrano 1 i de A 
Reproduced from Hung, Marks and Tardrew (4). 
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The formation of erythromycin from erythranolide A involves two 
alternative pathways during biosynthesis, leading by one route to 
erythromycin Band C and an intermediate compound and by another route 
to erythromycin A and another intermediate compound (Fig.1.2) (4). 
Erythromycin exists in many different forms, including at least two 
hydrates and an anhydrate (5). 
Anhydrous erythromycin has a melting point of 190-193°C and an optical 
rotation of [a]~5 = -78°C (2% in ethanol); the monohydrate and 
hydrochloride salt, have melting points of 137-140°C and 170-173°C 
respectively (3). Erythromycin is a colourless, bitter tasting 
substance poorly soluble in water (1-2 mg/L), readily soluble in most 
alcohols, acetone, chloroform and ether (6). It is a weak base 
(pKa 8.8) which is unstable in acidic or alkaline solutions and shows 
its maximum stability between pH 6.0 and 9.5 (7). The principal acid 
degradation products are 8,9 anhydroerythromycin and the 6,9 hemiacetal 
of 8,9 anhydroerythromycin (Fig.1.3) (8). 
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FIGURE 1.3 Chemical structures of the predominant acid 
degradation products of erythromycin 
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Aqueous, alcoholic solutions buffered at pH 7.0-8.0 are stable for 
one week under refrigeration (4°C) (7) and for three months when frozen 
(-10°C) (9). The dry powder is stable, but it is suggested that it be 
stored in the dark below 30°C in airtight containers (6). 
1.2 CHEMICAL DERIVATIVES OF ERYTHROMYCIN 
As discussed, erythromycin is susceptible to inactivation by acid, 
resulting in decreased absorption of orally administered erythromycin 
due to exposure of the drug to gastric secretions (10). Chemical 
modifications of the basic drug moeity have been performed in order to 
protect the active moeity from acid degradation. The most commonly used 
of these erythromycin derivatives are the stearate (an insoluble salt), 
the ethylsuccinate (an ester) and the estolate (the lauryl sulfate salt 
of the propionyl ester) (11). 
Two water soluble salts, erythromycin lactobionate and glucoheptonate, 
have been prepared for intravenous (i.v.) erythromycin formulations. 
The structures of all of the above compounds are depicted in Fig. 1.4. 
1.3 CLINICAL PHARMACOLOGY OF ERYTHROMYCIN 
1.3.1 Mode of Action 
erythromycin penetrates the cell wall of sensitive bacteria (12) and 
attaches to the 50S ribosomal subunit donor site in the presence of 
ammonium or potassium ions (13). A single molecule of erythromycin 
attaches to each ribosomal fragment (12). It prevents the incorporation 
of certain amino acids (lysine, phenylalanine) into the polypeptide 
linkages, but has no effect on the synthesis of nucleic acid (13). 
Although it acts by inhibiting protein synthesis, erythromycin may be 
either bacteriostatic or bactericidal depending on the sensitivity of 
the particular microorganism and the concentration of the drug (14). 
Its selectivity for micro-organisms is due to the absence of the 50S 
subunit on the ribosomes of the human host (15). 
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1.3.2 Antimicrobial Spectrum 
Erythromycin is active against most gram-positive bacteria and some 
gram-negative organisms, with an overall spectrum of activity similar 
to that of penicillin G (12). Typical in vitro sensitivities of 
organisms to erythromycin as reported by Nicho l as (14) are summarized 
in Tab le 1.1. 
TABLE 1. 1. Typica l in vitro sensitivities of organisms to 
eryth romyc 1 n 
Organism 
S. aureus 
Streptococcus pyogenes 
Streptococcus pneumoniae 
Streptococcus viridans 
Clostridium perjringens 
Listeria monocytogenes 
Corynebacterium diphtheriae 
Actinomyces israelii 
Nocardia asteroides 
Neisseria meningitidis 
Neisseria gonorrheae 
Hemophilus injluenzae 
Bordatella pertussis 
Bacteroides jragilis 
Brucella species 
Mycoplasma pneumoniae 
Mycobacterium kansasii 
Agent of Legionnaires ' disease 
Reproduced from Nicho las (14). 
Typical Minimum 
Inhibitpry Concentration 
(micrograms per 
milliliter) 
Mean Range 
0.4 0.00S->100 
0.04 0.00S-0.8 
O.OS 0.006-0 .2 
0.06 0.02-0. 1 
O.S O.OS-S 
0.16 0.1-0.3 
0.02 0.006- 0.2 
O.S 0.2-0.S 
2S . 0 0.2->200 
0.4 0.1-0.8 
0.1 O. OOS-O.4 
3. 1 0.1 -6 
0.3 0.02-1. S6 
1.S 0.12->128 
S 0.3-10 
O.OOS 0.001-0.01 
0.S-2 
<u.S 
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In addition, erythromycin is active against some atypical mycobacteria, 
Ch2amydia and some rickettsiae (12). The development of resistance by 
staphylococci, Haemophi2us inf2uenzae, and some pneumococci has 
decreased the use of this drug as first-line treatment of infections 
caused by these bacteria (12). 
1.3.3 Resistance 
Resistance to erythromycin appears to be related to a unique plasmid-
determined mechanism by which the target site and not the antibiotic 
itself is changed. Strains of Staphylococcus aureus resistant to 
erythromycin have been shown to contain an enzyme which methylates 
specific sites on the 50S ribosomal subunit inhibiting the binding of 
erythromycin which is vital for its antibacterial action (14). 
Metabolites of erythromycin, isolated from human urine, have been shown 
to be possible inducers of resistance (16). 
Staphylococci, resistant to erythromycin, have been reported to be 
resistant to all other macrolide antibiotics tested. The degree of 
this cross resistance varies considerably from strain to strain but may 
extend to all drugs acting on the 50S ribosomal sub-unit (17). 
1.3.4 Adverse Reactions 
Erythromycin is generally regarded as the least toxic of the commonly 
used ant ibi otics (14). Mild degrees of epigastric distress, nausea , 
vomiting and diarrhoea are fairly frequently encountered with oral 
erythromycin, but these symptoms are only rarely serious enough to 
require cessation of therapy (18). Allergic effects occur in about 0.5 
per cent of patients (17). Most patients receiving i.v. erythromycin 
experience burning sensations in the infused vein often with phlebitis, 
necessitating frequent changes of the infusion site (12). 
Cholestatic hepatitis may occur after oral use of erythromycin 
estolate, and ethylsuccinate (18), the signs and symptoms of which, 
range from mild to moderate abdominal discomfort with jaundice, to 
symptoms of acute cholecystitis (12). The reaction usually develops 
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after 10 to 21 days of continuous therapy and is more prevalent in 
adults than in children (14). Once medication is discontinued, 
recovery is prompt, although residual hepatic dysfunction has been 
reported (15). The generally accepted hypothesis that erythromycin 
·estolate is a more frequent cause of jaundice than any of the other 
erythromycin derivatives , has recently been challenged. From the 
results of prescription-event monitoring of over twelve thousand 
patients receiving erythromycin estolate or erythromycin stearate it 
was concluded that the incidence of this side effect is unlikely to be 
more than one in a thousand using either drug (19). In addition, 
erythromycin stearate was responsible for three cases of erythromycin 
induced jaundice, whereas erythromycin estolate could not be implicated 
in any cases. In a controlled clinical study the estolate was found to 
cause no changes in normal liver function in 32 patients after a ten 
day period of administration (20). However, in a biochemical study, 
erythromycin estolate was found to have more cytotoxic potential than 
erythromycin base or propionate, causing leakage of enzymes from Chang 
liver cells at far lower concentrations than the other two drugs 
tested (21). 
1.3 .5 Drug Interactions 
Erythromycin has been reported to affect the hepatic elimination of 
some drugs, the most important being theophylline and carbamazepine 
(22). The interaction between erythromycin and theophylline has been 
extensively studied. Some investigators have reported no interaction 
between these drugs, although many reports in the literature indicate 
that in clinical practice an interaction can be anticipated (23,24). 
This results in increased serum theophylline concentrations and hence 
possible toxicity. The mechanism of the interference is unclear, but 
is presumed to be due to competitive inhibition of a demethylation 
pathway during hepatic metabolism (23). 
It has been suggested that in clinical practice a 25% reduction in the 
theophylline dose may be desirable in patients given more than six days 
concomitant treatment with erythromycin (23). Decreased serum 
erythromycin area under the curve values have been reported after the 
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co-administration of theophylline (25). Various possible explanations 
for these findings, including decreased absorption, altered protein 
binding and increased liver blood flow were discussed by the authors. 
Increased serum carbamazepine concentrations and associated toxicity 
have been reported after the co-administration of erythromycin (24). 
The cause of this interaction is presumed to be similar to that of the 
erythromycin - theophylline interaction. Recently Wong et aL. (26) 
reported that the clearance of oral carbamazepine (single dose) was 
decreased by the co-administration of erythromycin, whereas the 
apparent volume of distribution, elimination rate constant and 
absorption rate constant were unchanged. Further studies in this field 
using multi-dose regimes are necessary. This interaction should 
constantly be borne in mind when treating patients on long-term 
carbamazepine therapy with macrolide antibiotics (22). 
Erythromycin has also been shown to increase the prothrombin time of a 
warfarin stabilized anticoagulant patient by 40% after only three days 
of concomitant erythromycin therapy (27). 
1.3.6 Clinical Uses 
The efficacy of this antibiotic against so many gram-positive cocci and 
aga inst HaemophiLus inJLuenzae and MycopLasma pneumoniae makes it an 
excellent antibiotic for the treatment of most upper respiratory tract 
infections such as sinusitis, laryngitis, tracheitis, acute bronchitis 
and primary atypical pneumonia (15). For persons allergic to 
penicillin who require an antibacterial agent with the spectrum of 
penicillin G or V, erythromycin is the drug of choice, provided that 
penetration across the blood brain barrier is not required (12). 
The spectrum 
treatment of 
diseases (14), 
of erythromycin usage has been extended to include the 
Legionnaire's disease (14) and some genito-urinary 
including gonorrhoea and primary syphilis (18). 
Recent findings that erythromycin is one of the few commonly used 
antimicrobial agents which is not immunosuppressive and may even 
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potentiate host immune responses, may well extend its already extensive 
clinical usage (28). 
The usual oral dose is 1.0 to 4.0 g per day for adults and 25.0 to 
50.0 mg/kg per day for children. The dose is administered in divided 
doses (usually 2-4 times a day) so as to decrease gastro-intestinal 
intolerance (18). As an alternative to penicillin in the treatment of 
primary syphilis 2.0 to 4.0 g per day should be administered for 10-15 
days (15). 
Intravenous administration is reserved for the therapy of severe 
infections. · The usual dose is 0.5-1.0 g every 6 hours which may be 
given for as long as 4 weeks with no difficulty except for 
thrombophlebitis at the site of injection (18). 
1.4 PHARMACOKINETICS OF ERYTHROMYCIN 
1.4.1 Problems Associated with the Interpretation of Data Obtained 
from Published Pharmacokinetic Studies 
The interpretation of data obtained from published studies, concerning 
both the pharmacokinetics and comparative bioavailability of 
erythromycin is complicated due to variations in study design, meal 
composition and timing, concomitant fluid intake and assay methodology, 
all of which have been shown to affect the pharmacok inetics of 
erythromycin considerably (11). The microbiological assay methods used 
in the majority of these studies are only able to detect concentrations 
of active drug. They are unable to detect the presence of any 
metabolites/degradation products, but most importantly, cannot 
distinguish between the amounts of active base and i nactive parent 
ester, present after the administration of the ester derivatives of 
erythromycin. This has led to much confusion over the advantages of 
the various erythromycin derivatives available, as well as to some 
erroneous conclusions . 
Numerous criteria for the standardization of pharmacokinetic and 
comparative bioavailability studies have been proposed (11,29-32) . The 
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most important of these include the need for large numbers of subjects, 
a discriminatory assay technique and multiple dose studies (31). 
The control of study variables and the specificity of the assay method 
have been used in the following discussion as a means of weighting the 
significance of the findings of the various studies discussed. 
1.4.2 Absorption 
1.4.2.1 Erythromycin Base and Stearate 
Erythromycin base is absorbed intact, while erythromycin stearate, an 
insoluble salt of erythromycin, dissociates in the duodenum to 
erythromycin base, in which form it is absorbed (33). This absorption 
occurs predominantly in the small intestine, caecum and large intestine 
(34). Suppositories of erythromycin base are also well absorbed 
(35,36). 
Shortly after the introduction of erythromycin, the absorption of the 
drug after oral administration of erythromycin base capsules was 
reported as being adequate but irregular (10). The initial theory of 
possible gastric acid deactivation of the drug (10), was substantiated 
by the improved serum concentrations obtained in patients with 
pernicious anaemia who were known to have no gastric acid secretions 
(37) and in normal patients after the co-administration of the capsules 
with aluminium hydroxide gel (10). Specially formulated acid resistant 
coatings were then applied to erythromycin tablets which resulted in 
increased absorption of the drug (10,37). 
Erythromycin stearate which was originally prepared as an acid stable 
salt of erythromycin has since been found to be acid labile (38). This 
drug, which is formulated both as a tablet and a suspension for 
paediatric use, was also found to have increased absorption in patients 
with decreased gastric acid secretions (39). It is now predominantly 
formulated as a film coated tablet which provides sufficient protection 
for the acid labile drug (40). 
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Erythromycin base has been formulated as an enteric coated tablet but 
recently has become available as enteric coated pellets contained 
within a capsule (41). The effect of co-administration of food and 
other study variables on the bioavailability of these two drugs in the 
dosage forms discussed have been extensively studied. 
The effect of food on the absorption of drugs in general has been 
reviewed by Welling (42). In the study of erythromycin absorption, the 
timing of the dose in relation to food intake is particularly important 
in that food may delay gastric emptying time and hence expose the acid 
resistant coating of the formulations to acid for a sufficiently long 
period to cause their dissolution and hence the acid degradation of the 
drug (43). The results of these studies are contradictory in many 
cases and are summarized in the following discussion. 
Co-administration of food with the enteric coated erythromycin base 
formulation resulted in delayed but not decreased absorption (31, 
44,45). More consistent and increased serum concentrations were 
obtained after administration of the formulation cont aining enteric 
coated pellets, which were not affected by the co-administration of 
food (44,46,47,48). 
Many workers have found that erythromycin is absorbed better from film 
coated erythromycin stearate tablets when administered to fasting 
subjects (43,46,49-53), while others have found the absorption to be 
increased by the co-administration of food (40,44,54,55,56). A 
feasible hypothesis for this contradiction has been put forward by 
Malmborg (44) who stated that any observation on the advantages or 
disadvantages of concurrent food administration made from a particular 
make of tablet are valid for that tablet alone and not the substance in 
general. Bioavailability differences between five different film 
coated erythromycin stearate tablet formulations have been reported 
(57), which appears to substantiate this hypothesis. 
The volume of water co-administered with erythromycin stearate film 
coated tablets has been shown to have a dramatic effect on the 
absorption of the drug (43). The decrease in absorption of 
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erythromycin in fasting individuals when the accompanying water volume 
was reduced from 250 to 20 mL is clearly depicted in Fig.l.S. In this 
particular study (43) the absorption of erythromycin was decreased by 
food (all subjects received 250 mL water) with the type of meal having 
no additional effects on this reduction (Fig.l.S). 
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FIGURE 1.5 The effect of concurrent food and water administration on 
the absorption of erythromycin stearate 
Reproduced from We II i ng et aL. (43). 
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Eryth romyc i n base and erythromycin stearate cannot be termed 
bioequivalent on the results of the majority of the single dose studies 
discussed. However, after multiple dosage regimes as found in clinical 
practice, the 
the serum 
amount of drug absorbed when measured 
concentration time curve (AUC) and 
by the area under 
maximum serum 
concentration reached (Cmax) are similar for both drugs (58,59,60). 
Typical values for these paramaters odtained after a single dose study 
(58) using different formulations of erythromycin base and stearate are 
summarized in Table 1.2. 
TABLE 1.2 
DOSE 
I. 
Cmax 
(,g/mL) 4. 
7. 
I. 
AUCO_7h 
(,g/mL .hr) 4. 
). 
Comparision of maximum erythromycin 
Treatment (SOD m9 Dose Erythromycin) 
A B C 
BASE. ENTERIC BASE. ENTERIC BASE. ENTERIC 
COATED TABLET COATED TABLET COATED PELLETS 
FASTING NON FASTING NON FASTING 
1.62 (0.70) 0.23 (0.48) 1.52 (0.79) 
2.67 (0.72) 3.49 (1.48) 3.47 (1.23) 
4. 00 (1.43) 3.90 (2.39) 3.97 (2.13) 
4.32 (1.84) 0.31 (0.80) 3.63 (1.96) 
10.03 (3.70) 13.10 (5.32) 12.50 (5.18) 
15.53 (7.95) 14.75 (10.99) 15.10 (7.09) 
serum concent rat ions 
0 
STEARATE. FILM SIGNIFICANCE 
COATED TABLET OF DIFFERENCES' 
NON FASTING 
I.BB (1.19) A,C,D>B 
3.47 (1.91) NS 
3.72 (1.90) NS 
4.88 (2 .80) A ,e ,O>B 
11. 15 (6.69) NS 
11.24 (5.70) C>D 
... Difference significant at p<O.OI Standard deviation in parenthesis 
Reproduced from Kaheia and JSrvensivu (58). 
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1.4.2.2 Erythromycin Estolate 
Erythromycin estolate, unlike the base or stearate is acid stable (61). 
It is absorbed as the prop ionyl ester of erythromycin which does not 
have any significant antimicrobial activity until hydrolysed in vivo 
to erythromycin base (62). This hydrolysis occurs slowly and 
incompletely, with chromatographic studies showing that after an 
oral dose of erythromycin estolate only 20 per cent of the t otal 
drug absorbed is availab le as the active base (63). This tasteless 
derivative is formulated as a paediatric suspension or as a capsule. 
The non-specific nature of the majority of microbiological analytical 
methods used for the analysis of this derivative, 
in Section 1.4.1. In 1969 Stephens et aL (63) 
have been discussed 
described the first 
analytical method capable of discriminating between concentrations of 
inactive propionyl ester and active erythromycin base. The numerous 
studies (39,49,50 ,61,64-69), that have reported the overwhelming 
increase in bioavailability of erythromycin estolate over the base and 
other derivatives, need to be examined with a new perspective. Some 
observations made during these studies are not however dependent on the 
specificity of the assay method, the most important being the influence 
of concomitant food intake. 
Concurrent food intake with this erythromyc in derivati ve has been 
reported to result in increased (45,53), decreased (49,50) and 
unaffected absorption (70). Erythromycin estolate has also been shown 
to have a lower biliary excretion than the base (66). 
Bechtol et at . (71) have used a discriminatory assay technique (63) to 
study the bioavailability of the two most commonly formulated 
erythromycin paediatric suspensions, the estolate and ethylsuccinate. 
They found serum erythromycin base concentrations to be higher after 
administration of the estolate than after the ethylsuccinate. These 
erythromycin base concentrations were similar to those obtained after 
the administration of equivalent amounts of erythromycin base or 
stearate. These results have been verified by the work of Yakatan 
et aL (33), DiSanto et aL (72) and Welling et aL (53) who all 
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concluded that the estolate formulation was at best equivalent to the 
base and stearate formulations after multiple dosing, which is in 
disagreement with the majority of the earlier literature as discussed. 
Figure 1.6 depicts the considerable difference between the 
concentrations of the inactive ester and active base after repeated 
doses of an erythromycin estolate suspension when employing a 
discriminatory assay technique (53) . 
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FIGURE 1.6 Plasma concentrations of erythromycin propionate (ESTER) 
and erythromycin base (BASE) following repeated doses of 
erythromycin estolate suspension 
Reproduced from Welling et a1. (53). 
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1.4.2.3 Erythromycin Ethylsuccinate 
Erythromycin ethylsuccinate is a tasteless (6) acid stable derivative 
of erythromycin (55). It is absorbed as the intact ester, which has 
been reported to be biologically inactive and is subsequently 
hydrolysed to the active base in vivo (62). The reported increased 
bioavailability of this derivative in early studies was probably due to 
the lack of specificity of the microbiological assay method used. 
Since the development of a discriminating assay, it has been found that 
this ester results in slightly lower concentrations of active base than 
after the administration of erythromycin base, stearate or estolate 
(45,71, 73), but is still regarded as being clinically equivalent 
( 11 , 14, 24,74). 
1.4.2.4 Results of Specific Pharmacokinetic Studies on 
Erythromycin Absorption 
The following pOints have been summarized from the numerous 
pharmacokinetic studies which have attempted to characterize the 
absorption of erythromycin in terms of established pharmacokinetic 
concepts. 
A zero-order rate constant was found to most adequately fit the 
absorption data in three single dose (32,53,75) and one multiple-
dose study (76). Of the remaining multiple dose studies, two obtained 
best results when using a first-order absorption rate constant (53,77), 
while another found a combination of zero and first-order constants, or 
a series of first-order rate constants to fit the data most 
satisfactorily (78). 
The rate of absorption was found to change from dose to dose, 
being consistently lower after the third dose on anyone day than after 
the second (76). It was also found to decrease after multiple dosing, 
with the rate being consistently lower at "steady state" than after the 
first dose (53). 
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The absolute bioavailability of erythromycin stearate has been 
reported as being 53% for capsules, 48% for film coated tablets and 55% 
for a suspension in a single dose experiment (51) and 65% for a film 
coated tablet in a multiple dose trial (78). These bioavailability 
percentages are particularly low in that the first pass extraction for 
erythromycin has been reported to be less than 10% (78). 
Various workers have found it necessary to incorporate a lag-time 
function into curve-fitting programs after the administration of solid 
dosage forms of erythromycin (41,53,60,75-78) but not after the 
administration of suspensions (53). The formulations of enteric coated 
beads appear to have the longest lag-times (48). 
1.4.3 Distribution 
Erythromycin is well distributed throughout the body. Diffusion across 
the meninges is poor although therapeutic concentrations may be 
attained in the spinal fluid if meningeal inflammation is present (17). 
Placental transfer produces low serum concentrations in foetal blood 
although concentrations in the foetal liver are high (14,17). 
Moderately high concentrations of erythromycin appear in middle ear 
exudate and tonsil tissue (65) and good penetration into aqueous humor 
and mi lk has been shown in animal studies (79). Erythromycin is one of 
the few antibiotics which penetrates well into prostatic fluid (79). A 
small percentage of the drug is found in the urine, but sufficient 
concentrations for the inhibition of mos t pathogens are obtained (80). 
Recent studies us ing positron tomography (81) showed that an effective 
concentration of erythromycin was reached in the pneumonic lung within 
ten minutes after i.v. administration. 
Erythromycin is highly bound to serum proteins. The percentage of 
unbound drug after the administration of an erythromycin stearate 
formulation has been est imated to be 10 and 27 per cent by Wiegand and 
Chun (82) and Gordon et aZ . (83) respectively. The same workers found 
the percentage of unbound propionyl erythromycin to be 1.5 and 7.0per 
cent respectively, after the administration of an oral erythromyc in 
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estolate product. All of the commonly used analytical methods for the 
analysis of erythromycin measure the concentrations of both bound and 
unbound drug. Patients, having the same serum concentrations of 
erythromycin base after administration of erythromycin base and 
estolate formulations would therefore have approximately three to four 
times more drug available after the former therapy. 
Erythromycin, not surprisingly, has been shown to not bind 
exclusively to serum albumin. At least half of the bound drug has been 
associated with binding to ct - acid glycoprotein (84). A signi ficant 
correlation was found between increased erythromycin serum 
concentrations and increased amounts of ct- acid glycoprotein present 
in infected patients (84). This has important implications in the 
extrapolation of pharmacokinetic data obtained from normal trial 
subjects to the use of the drug in clinical situations. 
1.4.4 Metabolism 
trythromycin is N-demethylated in the liver of rabb its and rats to form 
des-N-methylerythromyc in (85) which is excreted predominantly in the 
bile (79,86), with smal l amounts being found in urine (87). 
Approximately 45% of the dose administered to rabbits is metabolized by 
this pathway per hour (85). In the rat, about half of the drug 
el iminated 
(87). In 
in the urine, bile and faeces was found to be unchanged 
a recent report (88) it was established that erythromycin 
induces its own metabol ism after repeated doses, by both increasing the 
number and activity of the microsomal enzymes involved in its 
metabolism. In humans, it has been shown that concentrations of 
erythromycin in bile exceed those of serum considerably (89). 
1.4.5 Excretion 
Th e amount of unchanged erythromycin eliminated in urine is smal l, 
averaging from 2-10% after oral dosage (60,77,90) to 15% after i.v. 
administration (80). Renal clearance has been estimated as being 13% 
and 76% of creatinine clearance in humans and dogs respectively (91). 
Renal tubular reabsorption in humans is suspected (91,92). 
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Erythromycin and des -N-methylerythromycin are excreted through t he 
bile, which contains high concentrations of these two substances after 
both oral and i .v. dosing. Biliary excretion has been proposed as being 
the major excretion pathway of erythromycin and its metabolites 
(15,17,89). Secretion of erythromycin across the wall of the jejunum 
into the lumen of the small intestine has been demonstrated in both t he 
rat and rabbit after i.v. administration (86,93). 
The pharmacokinetics of the distribution and elimination of 
erythromycin have not yet been convincingly characterized. In all of 
the i.v. studies reported (43,53 ,75,79,80,94 ) an open two-compartment 
model was found to describe the serum concentration - time curve most 
satisfactorily. 
In a comprehensive study, involving both i.v. (94) and oral dosages 
(78) of erythromycin to the same subjects, the i.v. and oral serum 
concentration-time profiles were best described by two-comp artment and 
one-compartment models respectively. Similar results were obtained by 
Welling et al. (53). The large inter-subject variations observed 
after oral adm inistration (78) were not found after i.v. dosage (94), 
indicating that these effects were presumably due to varied absorption 
and not differences in distribution or elimination. 
Of the other oral pharmacokinetic studies reported, a one-compartment 
model was found to best describe the data after single and multiple 
doses by some workers (43,77,95) while a two-compartment model was 
found to be most applicable by Kroboth et al. (75) after a single dose 
study. 
The most significant difference between single and multiple oral dose 
erythromycin studies was that the AUC, and hence bioavailability of the 
first dose, is conSistently less than that of the same dose of drug 
after a multiple dosing schedule. Using data from previous i.v. 
studies (94), Mather et at. (78) showed that the absolute 
bioavailability of an oral erythromycin stearate tablet was 30% after 
the first dose and 65% after the ninth dose. Similar results have been 
obtained by other workers (51,53,60,76). Colburn et at. (76) reported 
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an increase in the elimination half-life (t'f,~) of erythromycin from 
1.8 hr on day 1 to 2.6 hr on day 3 which may suggest saturati on of an 
enzymatic degradation pathway after day 1. leading to decreased 
elimination of the drug. From the findings of Danan et aZ. (88). who 
reported that erythromycin induces its own metabolism. an increase in 
metabolism would be expected (Section 1.4.4). Welling et aZ. (53) 
found the same increase in bioavailability after multiple dosing as 
discussed. with a concomitant decrease in the rate of absorption. 
indicating that this phenomenon was unlikely to be due to increased 
absorption. In a controlled chronopharmacokinetic study. DiSanto et 
aZ. (96) found the noon dose (180° from local midnight) to result in 
the highest AUC value on anyone day. This brief evidence of circadian 
effects on the pharmacokinetics of erythromycin does not. however 
explain the variations found over three days of multiple dosing. 
Impaired renal function has been reported not to affect the clearance 
of erythromycin (80). which would be expected. as only a very small 
percentage of the drug is excreted via the renal route (60.77.90) . 
Evidence of non-l inear erythromycin pharmacokinetics after i.v. 
administration has been reported (94). In this study a dose related 
increase in elimination half-life. volume of distribution and fraction 
of drug excreted in the urine were noticed. In a single dose oral 
study. Josefsson et aZ. (60) reported a non-linear increase in AUC 
values for increasing doses of erythromycin. as well as a trend towards 
an increased elimination half-life and fraction of dose excreted 
unchanged in the urine. 
This evidence certainly suggests some capacity limited degradation of 
erythromycin. presumably in the liver (60). resulting in decreased 
clearance and an increase in the unchanged drug available for uri nary 
excretion. Changes in protein binding cou ld explain the change in 
volume of distribution reported by Austin et aZ. (94). The extensive 
biliary excretion of erythromycin (89) and the active secretion of the 
drug into the small intestine (93) may well result in the increased 
concentrations of erythromycin found after multiple doses. as well as 
the apparent non-linear excretion. Similar observations made for 
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TABLE 1.3 Typi ca l pharmacoki netic parameters describing erythromycin 
disposition in relation to ora l dose 
(DOSE mg BASE) 
250 500 1000 500 (s t earate) 
SERUM 
n 20 22 21 22 
lag (h) 1.4 (0.3 ) 1.4 (O.B) 1.3 (0.4) 1. 1 (0 .4 i 
ka (h-1) 3.2 (1.3) 4.3 (2.2 ) 3.2 (1.B) 2.3 (0.7) 
ke (h-1) O.B (0.3) 0.5 (0 .1 ) 0.4 (0.1) 0.6 (0 .2) 
AUC 1 (mg/L/hr) 4.5 (1. 7) 11.2 (4.3) 27.2 (10.6) 7. 5 (3 .4) 
AUC2 (mg/L/hr) 5.4 (3.4) 13.2(4.1) 2B .6 (11.2) B.O (3 . 6) 
T% (hr) 2 . 0 (2 .0) 2.5 (1.0) 3.0 (1.7) 2.7 (2 .3) 
URINE 
n 10 11 10 10 
~ EXCRETEO 5.0 (3 . 00) 7 . 0 (2.00) 9 . 0 (5 .00) 4.0 (3.00) 
CIR(L/h) 3.0 (1.2) 3 . 5 (1.6) 2.9 (1.4) 2.7 (1.1) 
Standard deviation in parenthesis 
KEY n : number of people in trial 
lag : lag period between administration of dose and 
commencement of absorption 
ka absorption rate constant 
ke : el imination rate constant 
AUC 1 : area under the serum concentration-time 
AUC2 
curve calculated by the trapezoidal rule 
AUC calculated with the AUTOAN2/NONLIN program. 
% EXCRETED : Percentage of biologically active erythromycin 
excreted in the urine during 9 hours 
CI R : Rena l clearance 
Reproduced from Josefs son et aZ. (60) 
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another macrolide antibiotic. josamycin . have been explained by entero-
hepatic recycling (97). Biphasic serum concentration curves were 
evident in a few subjects in both an i.v. (94) and an oral study (60) 
indicating the possibility of signif icant entero-hepatic recycling. 
This phenomenon may be more prev alent than reported. as in many other 
studies individual variations such as these could have been ascribed to 
random variations and lost in the averaging of the data (94). Other 
explanations of these "humps and bumps" on serum concentration-time 
profiles have been discussed by Benet (98). 
Typical values for standard pharmacokinetic parameters obtained after 
oral administration of two erythromycin formulations are dep icted in 
Table 1.3. 
1.5 STUDY OBJECTIVES 
In view of the problems associated with microbiological methods 
currently used and the lack of suitable techniques to quant itative ly 
measure erythromycin concentrations in biological fluids. the main 
objective of this study was to develop a specific. sensitive. 
reproducible and rapid method for the quantitative determinati on of 
erythromycin and possibly some of its known metabolites and/or 
degradation products in serum and urine by HPLC with ultraviolet (U.V.) 
detection employing a conventional variable wavelength U.V. detector. 
It was felt that such a method would provide a powerfu l tool for the 
study of the biopharmaceutics and pharmacokinetics of erythromycin. 
Whilst not a primary objective of this study and in view of the recent 
reports published using HPLC with electrochemica l detection (9.99).the 
latter system was also investigated. 
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CHAPTER TWO 
DEVELOPMENT OF AN HPLC METHOD FOR THE ANALYSIS OF ERYTHROMYCIN 
2.1 INTRODUCTION 
Like all chromatographic techniques, HPLC may be defined as a 
differential migration process where sample components are selectively 
retained by a stationary phase (100). What sets HPLC apart from other 
techniques is its ability to accomplish this separation with great 
speed, sensitivity, and precision, and its applicability to an enormous 
variety of compounds (101). Recent advances in instrumentation, column 
engineering and theory have extended its field of application to 
virtually all branches of science and technology (102). 
The earliest stationary phases e.g. silica, were more polar than the 
mobile phases, which consisted of mixtures of non-polar organic 
solvents, resulting in an increased adsorption and hence retention for 
polar solutes. More recently, systems have been developed, where the 
relative polarities of the two phases are reversed and these are termed 
reverse phase HPLC. These systems employ non-polar stationary phases 
which are prepared by the covalent bonding of various hydrocarbon 
chains e.g octyl (CS) or octadecyl (C 1S ) to a silica support, and 
using mobile phases consisting of polar organic solvents mixed with 
water. In this form of chromatography the mechanism for solute 
interaction is a combination of partition chromatography, where 
molecules actually penetrate the bonded hydrocarbon layer, and 
adsorption chromatography where the non-polar molecules are attracted 
to the non-polar stationary phase. The solute behaviour is opposite to 
that in normal phase chromatography and yields advantages in the 
separation of certain classes of compounds, so much so that it is 
currently used for the majority of pharmaceutical applications (103). 
In the preparation of reverse phase packing materials, residual 
silanol groups on the silica packing support are known to 
interfere with the process of reverse phase chromatography. A 
second silanization reaction where the residual hydrogens of the 
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silanol groups are replaced with 
called "end-capping" and produces 
batch uniformity, improved column 
( 103 , 104) . 
trimethylsilane functions is 
columns of superior batch-to-
life and reduced peak tailing 
The object of chromatography is to separate components, within a 
reasonable, time into separate zones as they migrate through the 
column. This separation, or resolution, depends on three main factors; 
retention, column efficiency and column selectivity. 
In order to attain maximum resolution between two compounds, the 
compounds must ' be retained on the column for an adequate per iod of 
time. This is mainly due to the fact that the difference in elution 
time between two peaks becomes smaller as retention decreases, 
regardless of the column's efficiency or selectivity (101). 
FIGURE 2.1 
Retention time for: 
I-to~ unretained peak 
w 
Tangent lines 
are used in 
determining 
peak width 
at base{W) 
t- tA, I peak 1 
t-------------- t A, I peak 2 
Calculation of column performance parameters 
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In order to help in choosing the correct retention for maximum 
resolution between compounds it is necessary to define the parameter, 
the column capacity factor, k'. This is defined as follows for each 
peak (Fig. 2.1): 
(Equation 1) 
Once a column has been chosen, it is necessary to adjust the eluent 
strength so that the retention times for the peaks of interest are in 
the range of k' values between 1 and 10. 
Compounds which elute very late (k' >10). result in broad peaks which 
affect the detection limits. This is due to the slow movement of the 
zone of separation for these compounds through the column and hence 
from the column through the detector. The zone of separation is the 
same width for all peaks. irrespective of their retention. However. for 
early eluting peaks. it leaves the column travelling faster. resulting 
in sharper and hence more easily quantifiable peaks (101). 
There are two 
depicted in Fig. 
fundamental ways of improving resolution as 
2.2. The first is by decreasing peak width (zone 
width) while holding the zone centre separation constant and the second 
by increasing the zone centre separation while holding the peak width 
constant. The former method is termed the efficiency of the column and 
the latter the selectivity. 
Column 
affected 
multiple 
efficiency, which is a measure of zone spreading. is 
by three concurrent phenomena; longitudinal diffusion. 
flow paths and resistance to mass transfer (101). 
Long itud i na I diffusion along the column axis is of little 
consequence in HPLC as the analysis is completed in a short time 
when compa red to diffusion rates within the so I vent. This is in di rect 
contrast to gas chromatography. where diffusion rates within the 
carrier gases are much faster. resulting in significant decreases in 
column efficiency (101). Multiple f low paths lead to flow velocity 
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UNRESOLVED 
ZONES 
INCREASED 
EFFICIENCY 
INCREASED 
SELECTIVITY 
FIGURE 2.2 Improving peak resolution by increasing efficiency or 
selectivity 
inequalities and eddy diffusion, 
faster than others resulting in 
minimized by homogeneous packing 
particles (105). 
causing some molecules to travel 
increased zone widths. This is 
surfaces and uniformly packed 
Resistance to mass transfer or sorption-desorption kinetics is 
the major source of zone spreading, and may be reduced in 
numerous ways including the use of small particle-size packing 
substrates with monolayers of active surface, increased 
temperature and changes in flow rate (103). 
When comparing column efficiencies, the height equivalent to a 
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theoretical plate (HETP) is a useful parameter. The smaller the HETP 
value the smaller the zone width and consequently the greater the 
efficiency of the column. This parameter is most easily obtained from 
the calculation of the number of theoretical plates (N) of a column as 
follows (Fig 2.1); 
( tA )' N = 16 y:J- (Equation 2) 
The HETP is then obtained by dividing N by the length of the 
column (L). Modern columns have HETP values of 0.01 to 0.1 mm giving a 
25 cm column with an HETP of 0.2 mm about 12 500 plates. Increasing 
N and decreasing HETP leads to more efficient columns but it must be 
remembered that resolution, which is the ultimate goal of 
chromatography, is only proportional to the square root of the plate 
count (N). 
The 
the 
selectivity of a column, or the separation 
ratio of the capacity factors (Equation 
factor, is simply 
1) of the peaks. 
(Column Selectivity) a k' =-' k' , (Equation 3) 
Column selectivity i s a function of the properties of the 
stationary phase and eluting power of the mobile phase. The 
ability to change column selectivity by small changes in mobile 
phase composition is the most powerful tool in the optimization of 
resolution in HPLC (106). 
The choice of the solvent for use in reverse phase chromatography is 
complex and depends on numerous fa ctors including surface tension, 
dielectric constant, viscosity and eleutropic strength which are 
mainly linked to the polarity of the solvent (103). As a general 
rule, the column efficiency decreases with an increase in solvent 
viscosity and polarity. Water, the weakest eluent, is both the most 
viscous and polar, while methanol and acetonitrile which are strong 
eluents are less viscous and relatively non-polar. A mixture of these 
solvents normally provides a suitable mobile phase for the desired 
separation (101,103). 
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Column performance can 
buffer salts such as 
be further increased by the addition of 
citrate or phosphate. to the aqueous 
component of the mobile phase. Easily ionizable compounds 
interact with the polar residual silanol groups present on the 
packing substrate surface leading to increased retention and 
decreased peak shape. Buffer salts, besides keeping the pH of 
the mobile phase constant throughout the column are known to 
decrease this effect by masking the residual silanol groups via 
the reaction of the oxygen atom of the buffer molecule (107). 
In addition, the judicious choice of mobile phase pH can have a 
significant effect on the retention of weak acids and bases by 
suppression of ionization. Weak acids are made more hydrophobic, 
resulting in an increased retention by lowering of pH while 
the reverse is true for weak bases (101,106). Columns with silica 
substrates however. fail rapidly if a mobile phase of pH <2.00 or 
>7.00 is used due to t he increased solubility of silica in these 
pH ranges especially at increased temperatures (108). The life of 
the analytical column may be extended when working at these 
extreme pH ranges by the prior saturation of the mobile phase 
with silica from a silica saturating pre-column, or to a 
lesser degree, by the use of a conventional guard column (109). 
The particle size of the packing material and the flow rate used 
have an important effect on the efficiency of a given column. 
There are four major pOints which must be noted (110,111). 
1) The pressure resulting from a set flow rate of the same mobile 
phase increas~s when the particle size of the packing is 
decreased. 
2) There is an optimum flow rate at which the HETP for a column 
is minimum. Working at this flow rate yields the 
best resolution but does not necessarily provide the 
shortest analysis time. 
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3) Column efficiency is inversely proportional to the size of the 
column packing material. Shorter columns packed with small 
particles can provide similar separations to conventional 
columns, or columns of the same length can provide increased 
efficiencies when packed with smaller particles. 
4) The flow rate at which the column efficiency is maximum is 
inversely proportional to the particle diameter. 
As a consequence of the last two relationships the use of small 
particles can lead to decreased analysis time by the use of both 
shorter columns and increased flow rates (110). 
This has been the major cause of the trend towards using 
particle size packing substrates <10 ~m compared to the 
50 ~m pellicular packings originally used (110,112). These 
smaller 
larger 
large 
particle size pellicular packings are still used in guard columns due 
to their ability to be inexpensively dry packed. These guard columns 
which are placed prior to analytical columns to protect them from 
contamination, have been known to affect peak shape considerably when 
using highly efficient analytical columns (112). This has been 
circumvented by the production of guard columns containing small 
disposable cartridges, slurry-packed with the same packing material as 
the analytical column. 
A further application of this decrease in the particle size of the 
packing substrate has led to the development of high speed liquid 
chromatography (111). In this form of HP LC, extremely short columns 
(5.0 - 10.0 cm) are filled with packing substrates with an average 
diameter of only 3-5 ~m. Additional advantages of these 
columns can best be seen from a plot of HETP vs flow rate. 
Figure 2.3 shows such plots (Van Deemter curves) for three columns 
packed with C18 stationary phase particles of 3, 5 and 10 ~m 
diameter. From this plot it can be seen that for the column 
packed with 10 ~m substrate, as the flow rate is increased above 
the optimum of 0.5 to 1.0 mL/min the HETP value increases, 
decreasing column efficiency. The curve is much flatter for the column 
packed with 3 ~m packing material allowing the use of higher flow rates 
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FLOW RATE. mL/min. 
FIGURE 2.3 Relationship of the HETP to the mobile phase flow rate for 
three different columns containing C18 packing substrates with different particle diameters: 
A)3~mB)5~m C)10~m 
Reproduced from Di Cesare. Dong and Ettre (111). 
of 2.5 - 3.0 mL/min without a decrease in column efficiency. The 
associated increase in inlet pressure generated limits the use of even 
higher flow rates (111). 
The practical advantages of high speed liquid chromatography 
include a significantly improved chromatographic performance per 
unit time. leading to shorter analysis times and decreased solvent 
consumption. 
have affected 
There 
its 
are. however. distinct disadvantages which 
widespread acceptance. The main disadvantage 
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is the need for specialized equipment to decrease the effects of 
extra-column band width broadening which can negate the extra 
efficiency of the column, leading to the design of detectors containing 
micro-flow cells (1-3 ~L) and extremely fast response times (111). 
Special injectors with by-pass loops are also necessary to decrease the 
formation of column top-end voids caused by the pressure fluctuations 
of conventional injectors which are a distinct problem at the high 
pressures encountered. 
The packing of columns containing microparticulate packing substrates 
requires the use of high pressure slurry techniques to ensure maximal 
homogeneity and subsequent column efficiency (112). The main variables 
in slurry packing are the density and viscosity of the solvent and the 
composition, flow rate and pressure of the slurry (105). The use of 
carbon tetrachloride as the slurry solvent has been reported to result 
in columns of superior efficiency when compared to traditional slurry 
solvents such as methanol (113), presumably due to decreased particle 
size distribution during packing (114). 
There are various detectors available for use in HPLC which have 
recently been reviewed by White (115,116). The ultraviolet 
(U.V.) detector was one of the earliest HPLC detectors and is still 
the most popular due to its ease of operation, versatility and 
sensitivity (115). Any solute with a U.V. absorption can be 
monitored using this mode of detection. Recent technological advances 
in computers and electronics have led to a new generation of U.V. 
detectors having the ability to scan peaks on-line over a pre-
determined wavelength range, giving U.V. spectra that may be compared 
to documented U.V. spectra for positive peak identification. Data 
storage facilities have led to the post-run manipulation of 
chromatograms resulting in the most convenient choice of sensitivity 
and peak integration parameters. The advent of the diode-array 
detector has further extended the powers of the U.V. detector by having 
the facility to compare U.V. spectra at three different parts of a peak 
in order to validate peak purity and to detect any possible co-eluting 
contaminants. 
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There are no universally accepted criteria for the comparison of 
U.V. detectors but the concept of the signal-to-noise ratio (SiN) 
is well established (117). Any disturbance of a detector output that is 
unrelated to an eluted solute can be defined as detector 
noise. Short term noise which manifests itself as a "fuzzy" 
baseline is the most important and is mainly due to pump 
pulsations, dissolved gases in the mobile phase and unstable 
detector electronics (115,118). 
The limit of detection or sensitivity is defined as the amount 
of solute that will produce a signal, 
three times) the short-term noise level 
equivalent 
(115,117). 
to twice (or 
By injecting 
equivalent amounts of a compound using identical chromatographic 
conditions, two detectors may be compared in this manner by 
calculating their SiN ratios. 
It is not until the detector signal is fully amplified that the diverse 
nature of this noise i s revealed (1 19). When working at high 
sensitivities and low wavelengths (below 220 nm) the use of carefully 
purified solvents, correctly chosen for their U.V. cut off values, non-
absorbing buffer salts, freshly prepared HPLC grade water and 
met iculous cleaning of glassware are essential (103,119,120,121). 
Baseline noise caused by dissolved gasses in the mobile phase is due to 
the interaction between oxygen and the solvent and is best controlled 
by constant degassing. Thi s may be achieved by the constant purging of 
the mobile phase with helium (103), or by the use of an in-line vacuum 
degassing unit. Methods such as periodic ultrasonication or helium 
purging are less popular, as they cause sudden changes in mobile phase 
gas content resulting in detector baseline instability (118). 
The need for strict adherence to these precautions and others in high 
sensitivity bioanalyis is unfortunately not generally seen as being of 
great importance and is best descr ibed by Jones (119); "There is much 
ignorance of such problems amongst colleagues who carry out HPLC on 
similar samples at high analyte concentration in various chemical and 
pharmaceutical development laboratories where the knob of the detector 
amplifier is rarely turned past the halfway mark." 
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2.2 METHODS AVAILABL~ fOR THE ANALYSIS OF ERYTHROMYCIN IN RAW 
MATERIAL AND IN PHARMACEUTICAL DOSAGE FORMS 
2.2.1 Requirements of a Suitable Method 
The need for an analytical method to quantitatively determine 
erythromycin in biological fluids after the administration of the 
various erythromycin derivatives available, has been discussed in 
Section 1.4.1. Analytical techniques for the assay of erythromycin and 
its derivatives in raw material and in pharmaceutical dosage forms 
must be able to indicate both the purity and stability of the compound, 
before and after manufacture and storage. This is particularly 
important in that different batches of erythromycin raw material have 
been reported to differ in the amount of the various erythromycin 
components present (2,122). In addition, solutions of erythromycin 
base are only stable for one week (4°C), even when buffered at 
pH 7.00 - 8.00 (7), making the detection of degradation products of 
the utmost importance. 
2.2.2 ~iicrobiological Analysis 
80th the USP (123) and BP (124) official assays for the analysis of 
erythromycin use microbiological techniques. The capability of the 
sample to inhibit growth of a susceptible organism is measured and the 
results compared with those obtained with standard solutions of known 
concentrations of erythromycin. StaphyLococcus aureus is employed for 
the turbidometric procedure (125) and Sarcina Lutea or BaciLLus pumiLus 
for the plate assay (123,124,126,127). The inability of these methods 
to differentiate between erythromycin base and any other components or 
degradation products present, has led to the development of more 
selective methods for the analysis of erythromycin in raw material 
and/or dosage forms. While being sufficiently sensitive, these 
microbiological assay methods have been reported as being relatively 
imprecise (128) and are extremely tedious to perform. 
\ 
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2.2.3 Ultraviolet Spectrophotometric Analysis 
The ultraviolet spectrophotometric assay for erythromycin first 
described by Kuzel et aZ. in 1954 (129), has since been automated by 
the same workers (130) and is applicable to dosage form and 
fermentation broth analyses. The method is based on mild alkaline 
hydrolysis of erythromycin with 0.25 N sodium hydroxide at 65°C which 
produces a chromophore having an absorbance peak at 236 nm. In order 
to determine materials other than erythromycin which absorb at this 
wavelength, a sample blank is prepared by mild acid treatment of the 
sample with 0.50 N sulphuric acid. This converts the erythromycin 
present to anhydroerythromycin which does not absorb U.V. radiation at 
the wavelength used. While being able to perform up to 300 
determinations per day, this method is non-specific and hence not 
stability-indicating. 
2.2.4 Colorimetric Analysis 
Kuzel and Coffey (131) developed a sensitive and precise method based 
on the ion-pair-dye complex of bromocresol purple (5,5,-dibromo-o-
cresol-sulphonphthalein) and the desosamine moeity of erythromycin in 
pH 1.2 buffer. This method, like that of Sanghavi and Chandramohan 
(132) who used p-dimethyl amino benzaldehyde as the coupling agent, 
lacks specificity for erythromycin since all tertiary amines are 
measured. These methods are capable of detecting erythromycin in 
dosage forms and fermentation broths in a concentration range of 10.00-
100.00 )Jg/mL. 
2.2.5 Chromatographic Analysis 
2.2.5.1 Column Chromatography 
A technique using a silica gel glass column, for the separation of 
erythromycin on a preparative scale has been reported by Banaszek et 
aL (133). 
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2.2.5.2 Thin Layer Chromatography 
A number of thin layer chromatographic systems (tIc) have been 
described for the separation of erythromycin, from its derivatives and 
components (7,133-138) . The method of Radecka et aL ( 135) us i ng 
densitometric detection is the only method available for the 
quantitative analysis of erythromycin by tIc. Thin layer and paper 
chromatographic methods combined with bio-autography have been 
described for the 
biological fluids 
analysis of erythromycin and 
(Section 3.1). These methods 
its derivatives in 
however, can only 
detect microbiologically active erythromycin components and are thus 
unsuitable for detailed analysis of erythromycin in raw materials 
and/or dosage forms since they are not stability-indicating. 
2.2.5.3 Gas Chromatography 
A gas chromatographic method for the determination of erythromycin and 
its derivatives following silylation with a combination of three 
trimethylsilyl derivatives in pyridine has been reported by Tsuji and 
Robertson (2). This method is able to quantify the proportions of 
erythromycin A, S, C, anhydroerythromycin, erythralosamine and the 
propionate esters of erythromycin in dosage forms following 
chromatography on an OV-225 or PPE-20 column at 275°C with flame 
ionization detection. Ten micrograms of silanized erythromycin were 
injected onto the column although this could be decreased to 100 ng 
with the use of a lower attenuation setting. Results of samples 
analysed by this technique were found to compare well with those 
determined by microbiological assay methods. This procedure, 
has not found wide-spread use possibly due to the lengthy 
time (24 hrs at 75°C) and the instability of the g.c. column 
2.2.5.4 High Performance Liquid Chromatography (HPLC) 
however, 
silylation 
(7) . 
The first reported HPLC technique for the determination of erythromycin 
was by Omura et aL. in 1973 (139). These workers used a reverse phase 
Jascopak column for the separation of macrolide antibiotics in general. 
They reported retention times of 3.0 and 2.4 min for erythromycin A and 
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B respectively using U.V. detection at 232.5 nm. 
White et a2. (140) also reported the separation of 
reverse phase column (Lichrosorb C18 10 ~m) when 
general applicability of HPLC with small particle 
erythromycin on a 
investigating the 
size columns to 
antibiotic analyses. A refractive index detector was used which was 
able to detect an on-column load of 10.00 ~g. 
A normal phase method using a Corasil 2 (silica gel) column with 
chloroform as mobile phase has been used to distinguish between 
erythromycin and anhydroerythromycin (141). 
These methods (140,141), while being able to detect erythromycin and 
possibly one major degradation product, are not suitable for the 
detailed quantitative analysis of erythromycin in raw material or in 
pharmaceutical dosage forms. Suitable methods for this purpose have 
been developed by Tsuji et a2. (142-145). The first method reported 
(142) was able to separate erythromycin from its components using a 
~Bondapak C18 reverse phase column with U.V. detection at 215 nm. This 
method was later adapted for use in monitoring erythromycin in 
fermentation broths (144). The analytical column was changed to a 
Lichrosorb C18 5 ~m column preceded by a C18 guard column for the 
analysis of erythromycin ethylsuccinate and its components in dosage 
forms (143). Both the analytical and guard columns were maintained at 
10°C resulting in good separation of all components with excellent 
peak shape. 
A further method utilizing an increased column temperature (IOOe) for 
the separation of erythromycin base and its components was reported 
as an improvement over the original method (145). An internal 
standard, calusterone or megestrol acetate was utilized in the analysis 
of erythromycin base tablets which compared favourably with results 
obtained by the microbiological assay method (123). 
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2.3 EXPERIMENTAL 
2.3.1 Reagents 
Reagents were of at least analytical grade and the 
(Burdick and Jackson) was distilled-in-glass grade. The 
used in the mobi Ie phase was purified through 
System (Waters Associates) (Fig. 2.4). 
1) Deomed reverse osmosis system - for initial purification of 
water 
2) Storage tank 
3) Super-C cartidge - for removal of dissolved organic material 
4 & 5) lon-Ex cartridges - mixed bed deionizing resins for removal 
of dissolved inorganics 
6) Drganex-Q cartidge - for removal of last traces of organics 
such as some amino compounds generated 
by the anionic exchange resins 
7) Milli-stack unit - for removal of all microorganisms and 
particles larger than 0.22 ~m 
FIGURE 2.4 Milli-Q-Water Purification System 
acetonitrile 
HPLC water 
a Milli-Q 
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Drug samples used: 
Erythromycin Base USP 1 Lot No MO H-1 
Erythromycin Estolate USP Lot No MO F 
Erythromycin Ethylsuccinate 2 Lot 51-039-CO 
2 Erythromycin Stearate 
Erythromycin B 2 
Anhydroerythromycin 2 
Erythromycin Enol Ether 2 
Erythralosamine 2 
Oes-N-methylerythromycin 3 
Oleandomycin phosphate 4 
Triacetyl oleandomycin 
Josamycin 5 
4 
Lot 07-616-CO 
Lot 84-991-AX 
Lot 86-188-AX 
Lot 3511-55A 
Lot 26-978-AX 
Lot 164-171-185-2 
Lot 206/767003 
Lot 07305-76EA 
Lot W-285 
1) USP Reference Standards, Rockville, USA. 
2) Abbott Laboratories, North Chicago, USA. 
3) Lilly Laboratories, Indianapolis, USA. 
4) Pfizer Laboratories, Pietermaritzburg, South Africa. 
5) Yamanouchi International Ltd., Tokyo, Japan. 
Solutions of these samples were prepared in A-grade glassware by the 
addition of HPLC grade water, U.V. grade acetonitrile or a mixture of 
both. 
2.3.2 High Performance LiquId Chromatographic System 
The high performance liquid chromatographic system used throughout this 
analysis is depicted in Fig. 2.5. 
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FIGURE 2.5 High Performance Liquid Chromatographic System. 
-
_. 
6 
3 
1) Model ERC-350 Solvent degasser (ERMA Optical Works) Fig. 2.6 
2) Model M 6000A Solvent delivery system (Waters Associates) 
3) Model 710B WISP Automated sample injector (Waters Associates) 
4) Column - see section 2.3.5 
5) Model 769 Variable wavelength U.V. detector (Kratos Analytical 
Instruments) 
6) Model 561 Strip chart recorder (Perkin-Elmer) 
Solvent 
Pressure 
sensor 
Control 
circuit 
Vacuum Tubular plastic 
container membrane 
Vacuum pump 
HPLC 
pump 
The solvent to be degassed passes through the tubular plastic 
membrane, with its surroundings maintained in a vacuum. Only gas 
is allowed to cross the membrane while the solvent is passing 
through it 
FIGURE 2.6 Solvent Degasser: Principle of Operation 
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2.3.3 Additional Equipment 
1) Model 601 digital ionalyser (Orion Research) 
2) Speed-Vac concentrator (Savant Instruments) 
3) Whirlimixer (Fisons) 
4) Type 2474 five figure precision balance (Sartorious) 
5) Ultrasonic cleaner (Branson) 
6) Microfiltration centrifuge (Bioanalytical systems) 
7) Type BD filter membrane (Millipore Corp) 
8) Model LC-22 temperature controller (Bioanalytical systems) 
9) Model 730 Data module (Waters Associates) 
10) Magnetic stirrer (Gallenkamp) 
11) Column Packer (HPLC Technology) 
2.3.4 Ultraviolet Detectors 
1) Kratos Instruments Model 769 Variable wavelength Detector 
This detector which was fitted with an 8 ~l flow cell was operated 
predominantly at 200 nm at the maximum sensitivity setting of 0.01 
absorbance units full scale (AUFS). The variable time constant was 
varied between 1.0 and 2.0 sec. Set at these conditions, this detector 
was used as the standard for the comparison of the other detectors 
tested. For this purpose, it was placed in-line after the detector 
being evaluated, which was set at 200 nm with a time constant equal to 
that of the Kratos detector and at the maximum sensitivity setting 
which allowed an acceptable baseline. A sample of erythromycin, or 
internal standard, was injected into the chromatographic system in 
order to compare the peak height to baseline noise (SIN ratios) of the 
two detectors. Factors such as signal stability (drift) and peak shape 
were also considered. 
2) Waters Associates Model 490 Variable Wavelength Detector 
The model used was a prototype, fitted with a standard taper-cell 
design flow cell. Various additional features such as multiple 
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wavelength programming and the ability to scan peaks over a specified 
wavelength range are available on the commercial product. It was 
operated at wavelengths between 200 and 210 nm with a time 
constant of between 1.0 and 5.0 sec and at sensitivity settings of 
between 0.001 and 0.05 AUFS depending on the wavelength used. 
3) Beckman Instruments Model 165 Variable Wavelength Detector 
This detector had similar extra features to that of the Waters 490 
detector with the ability to substantiate peak identification by the 
scanning of a peak over a set wavelength range. It was fitted with a 
flow cell having a 13 ~l illuminated volume and was operated at a 
wavelength of 200 nm and at a sensitivity of either 0.01 or 0.02 AUFS. 
The response time was controlled by the setting of the baseline slope 
parameter to a value of 300. This introduced an active filter which 
set the variable time constant to 2 sec for maximum baseline stability, 
reverting to 0.01 sec on detection of a peak. 
4) Philips PU 4021 Diode-Array Detector 
This was the first of two diode-array detectors used, which in general 
have many additional features for the validation of peak purity and 
identity. This detector had an 8 ~l flow cell and was operated at 
200 nm and 0.01 AUFS. A few of the additional features including the 
scanning of peaks were also tested. 
5) Hewlett Packard 1040A Diode-Array Detector 
This detector which had a standard 3.5 ~L flow cell was controlled and 
assisted by the following components; An HP 85 personal computer, an HP 
9121 dual disc drive and an HP 7470A X-V plotter. It had the usual 
facilities of a diode-array detector with the additional advantage of a 
data storage facility which allowed the post-run manipulation of 
chromatograms as well as the ability to monitor and permanently store 
the results of chromatograms monitored at eight different wavelengths. 
The detector was usually set to monitor four different wavelengths; 
195, 200, 205 and 210 nm with the sensitivity adjusted during post-run 
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manipulations to give the best SIN ratio. It was also used for the 
scanning of peaks and the generation of 3- dimensional plots of 
absorpt ion vs time vs wavelength. 
2.3.S Mobile Phase Preparation 
The O.OS M phosphate buffer used in these studies was prepared by 
adding 3.2 mL phosphoric acid to 1.0 L of freshly prepared HPLC grade 
water. Sodium hydroxide pellets were then added to the acid/water 
mixture with constant stirring on a magnetic stirrer until the desired 
pH of the buffer had been attained. All other buffers used were 
prepared by dilution of this buffer solution. 
Mobile phase composition is reported as the relevant volumes of 
organic and aqueous components that were added to make 100.0 mL of 
mobile phase without correcting for molar volume changes, i.e. 
SOO.O mL of a mobile phase, O.OS M phosphate buffer/acetonitrile 
(70/30), pH 6.S0 was prepared by mixing 3S0.0 mL of O.OS M phosphate 
buffer with lS0.0 mL acetonitrile. Where the final mobile phase was 
adjusted to a pH value after addition of the two phases, this has been 
reported as the corrected pH. The solvent mixture was degassed and 
filtered through a 0.6 ~m filter prior to use. 
2.3.6 Columns and Mobile Phases 
(i) ~18 Reverse Phase Column (10 ~m) 
This, the first column used, was a 2S cm x 3.9 mm i.d. steel column 
packed with Techsil 10 ~m octadecylsilane (C 18 ) material (batch 
number T-06-10, HPLC Technology) by the method described in section 
2.3.8. Preliminary studies were performed on this 
included the affect of both buffer strength and mobile 
co l umn. These 
phase pH on the 
retention of erythromycin. The choice of the optimum mobile phase and 
operating conditions for this column are summarized as system A in 
Table 2.1. 
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(ii) ~18 Reverse Phase Column (5 ~m) 
A 25 cm x 3.9 mm i.d. column was packed with Techsil 5 ~m C18 
material. The optimum operating conditions for this column are 
summarized as system B in Table 2.1. The effect of increased 
temperature on the resolution between erythromycin and the internal 
standard (oleandomycin phosphate) was studied over a range from 25°C to 
48°C. 
(iii) ~18 Reverse Phase High Speed Column (3 ~m) 
This commercially available high speed column was only 7.5 cm long 
with an internal diameter of 4.6 mm. It was packed with 3 ~m C18 
material (Ultrasphere - ODS, Beckman Instruments). Numerous mobile 
phases, differing in organic/aqueous phase ratios, buffer strength and 
mobile phase pH operated at flow rates of between 1.1 and 
2.5 mL/min were tested in order to obtain a suitable separation 
between erythromycin and the internal standard. The best combination 
of these variables is reported as system C in Table 2.1. When the 
formation of a top-end void became evident it was repaired by 
application of a paste of Techsil 5 ~m C18 in methanol. 
(iv) Novapak C18 End -Capped Reverse Phase Column (5 ~m) 
This commercially available 15 cm x 3.9 mm i.d. column was packed with 
end-capped 5 ~m C18 material (Novapak, Waters Associates). Two 
slightly different sets of operating conditions for this column are 
reported as systems D and E in Table 2.1. The use of a guard column and 
of a silica saturating pre-column were investigated in addition to the 
effects of changes in flow rate and column temperature. During these 
studies the use of an in-line vacuum degassing unit as well as in-line 
ultrasonic degassing of the mobile phase were compared. 
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TA8LE 2.1 High performance liquid chromatographic systems used 
HPLC COLUMN MOBILE PHASE FLOW RATE TEMPERATURE PRESSURE 
SYSTEM (PHOSPHATE BUFFER) 
A C18 REVERSE 0.05 14 BUFFER/ 1.0 ml/min Ambient 1100 psi 
PHASE 10 urn ACETONITRILE 
(TECHSIL) (SO/50), pH 7.00 
B C18 REVERSE 0.05 M BUFFER/ 1.0 ml/min 45°C 2000 psi 
PHASE Sum ACETONITRILE 
(TECHSIL) (SO/50), pH 7.00 
C C18 REVERSE 0 .005 M BUFFER/ 2 . 0 ml/min Ambient 3000 psi 
PHASE HIGH ACETONITRI LE 
SPEED 3 urn (SO/50), pH 7.00 
(UL TRASPHERE) 
D C18 REVERSE 0.05 M BUFFER/ 1.0 mL/min Amb ient 1500 psi 
PHASE ENO- ACETOIHTRILE 
CAPPED 5 urn (70/34) , pH 7.00 
(NOVAPAK) 
E C18 REVERSE 0.05 M BUFFER/ 1.0 ml/min 35°C 1500 psi 
PHASE ENO- ACETONITRI LE 
CAPPED 5 urn (70/30), pH 7.00 
(NOVAPAK) 
2.3.7 Pre-Columns and Guard Columns 
(i) Silica Saturating Pre-Column 
was placed in-line between the solvent delivery This column when used, 
system and injector. It 
dry packed with 37-53 ~m 
consisted of a 25 cm x 3.9 mm 
silica material (Solvecon 
Whatman). 
i.d. steel casing 
pre-column gel, 
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(ii) Rheodyne Guard Column Unit 
This guard column, which was adapted from a loop column system used 
with the model 7125 Rheodyne injector, was placed in-line immediately 
prior to the analytical column. It consisted of a guard column holder 
fitted with a 3 cm cartridge, slurry - packed with porous 10 ~m C18 
materi a 1. 
(iii) Guard-Pak Guard Column Unit (waters Associates) 
This unit, which consisted of a holder for disposable guard column 
discs containing densely packed beads of 10 ~m particles was placed in-
line immediately prior to the analytical column. Commercially 
available discs containing C18 and cyano (CN) material were used, as 
well as a disc packed in the laboratory with 40 ~m glass beads. 
2.3.8 Column Packing Procedure 
Columns were packed as follows using an HPLC column packer. Packing 
material from a used, 25 cm x 3.9 mm i.d. steel casing (~Bondapak, 
Waters Associates) was removed and the column thoroughly rinsed with 
acetone . The column end-frits and sieves were soaked in concentrated 
nitric acid for 5 min after which they were thoroughly rinsed with 
water and sonicated for 20 min in methanol. Three and a half grams of 
packing material (Techsil C18 , 5 or 10 ~m) was slurried in 30.0 mL 
u.v.- grade carbon tetrachloride and sonicated until dissolved. After 
loading the carbon tetrachloride mixture into the column packing 
reservoir, 120.0 mL of degassed and filtered U.V. grade methanol was 
pumped through the column at a pressure of 5 000 psi. After this 
period the column was inverted without interuption of flow and a 
further 120.0 mL methanol was pumped through the column. The methanol 
reservoir was constantly degassed by sonication. After removal from 
the column packer, the column was wa shed with 50.0 mL 
acetonitrile/water (75 / 25) and tested using this mobile phase and a 
standard laboratory test mixture prepared as follows: 
90% r-j --------
[mAUJ \ 
o I =------=-
-10.0 1 I I 
19 .0 294.0 394.0 
Wovc;;alc;;angth [nmJ 
FIGURE 2.7 Ultraviolet spectrum of erythromycin in mobile phase 
0.05 M phosphate buffer/acetonitrile (70/30) . pH 7.00 
.:> 
....., 
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Ten milligrams of both benzamide and benzephenone, plus 0.5 mL 
benzene were made up to 20 .0 mL with acetonitrile. One mil Ii litre of 
this solution was diluted to 50.0 mL with acetonitrile/water (75/25). 
Two microlitres of this solution were injected onto the column at a 
flow rate of 1.0 mL/min, with U.V. detection at 254 nm, a sensitivity 
setting of 0.04 AUFS and a chart speed of 1 cm/min. 
2.4 RESULTS AND DISCUSSION 
2.4.1 Detector Wavelength 
Erythromycin absorbs in the low ultraviolet wavelength range but its 
inherent molar absorptivity is poor (146). The need to detect low 
concentrations of erythromycin in biological fluids (0.25-
5.00 ~g/mL) necessitated the choice of a wavelength where the 
absorbance was relative ly high. From Fig. 2.7 it can be seen that 
erythromycin only significantly absorbs U.V. radiation below 215 nm 
with a wavelength of 195 nm giving the highest absorptivity. A 
wavelength of 215 nm has been shown by Tsuji and Goetz (142) to 
provide sufficient sensitivity when monitoring high concentrations of 
erythromycin such as those found when analysing dosage forms of the 
drug . The need for maximum sens itivi ty led to the choice of 200 nm as 
the wavelength of detection, as wavelengths below 200 nm yielded 
unacceptable baseline noise and drift, while those above did not 
provide sufficient sensitivity. Figure 2.8 depicts the decrease in 
detector sensitivity resulting from an increase in detector wavelength 
from 195 to 210 nm. 
2.4.2. Detector Choice (See Table 2.2) 
The Kratos detector was found to have the most favourable SIN ratio 
at 200 nm when set at its maximum sensitivity of 0.01 AUFS . As a 
result, it was used as the standard for the comparison of the various 
detectors as previously described and was used for the majority of 
analyses throughout this study. The Waters prototype M490 detector 
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FIGURE 2.8 Chromatogram of erythromycin (1) monitored 
simultaneously at four different wavelengths 
COLUMN : Novapak 
A) 210 nm 
B) 205 nm 
C) 200 nm 
0) 195 nm 
MOBILE PHASE: 0.05 M phosphate buffer/acetonitrile (70/34), pH 7.00 
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TABLE 2.2 Comparison of U.V. detectors 
DETECTORS WAVELENGTH SENSITIVITY * SIN + COMPARATIVE 
(nm) SETTING RATIO SIN RAT 10 (AUFS) 
KRATOS SF759 200 0.01 44.0 
4.0 
WATERS 490 200 0.03 11.0 
KRATOS SF759 200 0.01 18.4 
1.0 
WATERS 490 210 0.002 19.4 
KRATOS SF759 200 0.01 38.0 
3.0 
BECKMAN 15S 200 0.02 14 .3 
KRATOS SF759 200 0.01 57.5 
3.0 
PHILIPS PU4021 200 0.01 1B.2 
KRATOS SF759 200 0.01 57 .2 
3.0 
HEWLE TT · PACKARD 
1040A 200 0.01 21.3 
* The Signal-to-noise ratios (SI N) were calculated as in section 2.3.4. 
+ The comparative SIN ratio i s the ratio of the SIN val ue of the 
Kratos detector to that of the detector under evaluation. 
introduced the concept of the compromise between the wavelength of 
maximum absorption and the wavelength at which maximum amplification of 
signal is possible. This detector, when set at the same conditions as 
the Kratos detector (i.e 200 nm, 0,01 AUFS, filter 2.0 sec), 
resu !ted in a baseline which was unusable due to excessive noise. 
Adjustment of the sensitivity setting to 0,03 AUFS resulted in a 
baseline similar to that of the Kratos detector with an expected 
decrease in the SIN ratio. Increasing the detector wavelength above 
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200 nm resulted in a dramatic decrease in baseline noise. This 
enabled the utilization of a detector sensitivity of 0,002 AUFS at a 
wavelength of 210 nm resulting in a comparable SiN ratio to that of the 
Kratos detector. The approximate four fold decrease in erythromycin 
absorption from 200 to 210 nm (Fig. 2.8) was thus compensated by a 
five fold increase in detector sensitivity. 
The Beckman 165 detector was found to have a far inferior SiN ratio 
than that of the Kratos detector when operated at 200 nm. This was 
mainly due to the increased baseline noise which only allowed a maximum 
sensitivity setting of 0.02 AUFS to be used. 
The Philips PU4021 detector was also found to have an inferior SiN 
ratio to that of the Kratos detector when operated at 200 nm and at a 
maximum sensitivity of 0.01 AUFS. The lack of a data storage 
capability inhibited the use of the peak scanning facilities to their 
full potential as these manipul ations had to be performed during a 
chromatographic run prior to the injection of the next sample which 
increased the overall analysis time and solvent consumption 
considerably. 
The data storage facility of the Hewlett - Packard 1040A detector was 
found to be extremely useful. Extensive-post run manipulation of the 
sensitivity parameters at various wavelengths however, still resulted 
in the optimum SiN ratio being inferior to that of the Kratos detector. 
This detector was mainly used for special applications, such as the 
monitoring of a chromatogram at four different wavelengths (Fig. 2.8) 
and the generation of three dimensional plots of absorbance vs time vs 
wavelength. These plots, provide a powerful means of determining both 
peak purity and the wavelength of choice for a mixture of compounds. 
The ability to detect des-N-methylerythromycin and the inability to 
detect anhydroerythromycin in the U.V. wavelength range from 195 to 
300 nm is depicted by such a plot (Fig. 2.9). 
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FIGURt 2.9 Plot of absorbance vs time vs wavelength for a mixture 
of des-N-methylerythromycin (1), erythromycin (2) 
and anhydroerythromycin (3), using the Hewlett-
Packard diode-array U.V . detector 
COLUMN : Novapak MOBILE PHASE: 0.05 M phosphate buffer/acetonitrile (70/34), pH 7.00 
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2.4.3 Choice of Internal Standard 
Oleandomycin phosphate was chosen as the internal standard from two 
other macrolide antibiotics, triacetyloleandomycin and josamycin. It 
was readily detectable at 200 nm and eluted prior to erythromycin on 
all chromatographic systems used. This necessitated the development of 
extremely efficient sample clean up procedures in order to separate 
both erythromycin and oleandomycin from interfering serum and urine 
components. Furthermore, oleandomycin co-eluted (Table 2.3) with 
des-N-methy lerythromycin, a known metabolite of erythromycin (85). 
Josamycin could not be used due to its long retention and relatively 
weak U.V. absorption at 200 nm, while triacetyloleandomycin was not 
detectable at all, using the chromatographic conditions optimized for 
erythromycin analysis (Table 2.3). 
2.4.4 Mobile Phase Selection 
The choice of the optimum mobile phase for the different columns used 
was governed by the need to separate erythromycin and the internal 
standard, the peak shape and the necessity of having a retention time 
for the internal standard of approximately 4 min in order to allow for 
the elution of endogenous components when applying the method to the 
analysis of biological fluids. 
The utilization of a detector wavelength of 200 nm limits the choice 
of possible mobile phase constituents. HPLC grade methanol, which has 
a U. V. cut-off of 205 nm (120) may be used in small percentages , but 
HPLC grade acetonitrile was chosen as it is superior both in 
transparency (U.V. cut off 195 nm) (103,120) and in eluting strength 
from reverse phase columns (Eleutropic value on octadecylsilane, 3.1 
vs methanol 1.0) (120). 
The necessity of having a buffer component in the mobile phase for the 
elution of erythromycin from a C18 column was established in 
preliminary studies (147,148). Erythromycin did not elute at all from 
these columns when a mobile phase of methanol/water or 
acetonitrile/water was used, while a mixture of either of these 
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solvents with a buffer component easily eluted the drug. A phosphate 
buffer was chosen due to its reported column efficiency and U.V. 
transparency at 200 nm (103). 
The molarity of the buffer was found to have a dramatic effect on the 
retention time and subsequent peak shape of erythromycin (Fig.2 .10). It 
was not possible to use a mobile phase of acetonitrile/0,05 M phosphate 
buffer (80/20) due to the insolubility and resulting precipitation of 
the buffer salts on mixing. 
Mobile phase pH was also found to have a substantial effect on the 
retention of erythromycin. As previously reported (142), the retention 
of erythromycin increased with an increase in mobile phase pH . 
The use of a mobile phase above the normally accepted pH limit for C18 
columns of 7.00 was investigated by the introduction of a silica 
saturating pre-column . This column, however, resulted in an unstable 
baseline when monitored at 200 nm, suggesting that the utilization 
of low U.V. wavelengths prevents the succesful applicat ion of this 
approach, possibly due to the U.V. absorption by the dissolved silica 
particles in the saturated mobile phase. 
As expected, the organ ic/aqueous phase ratio of the mobile phase had a 
consi derab le effect on both the selectivity and efficiency of the 
vari ous columns used, making it an important parameter in the 
optimization of chromatographic conditions (Table 2.1). 
2.4.5 Column Cho ice 
The 25 cm co l umn packed with 10 ~m C18 material (Techs il ) was found 
to be adequate for the initial studies of the effects of mobile phase 
composition on the retention of erythromycin. It, however, was unable 
to resolve erythromycin from the internal standard, which led to the 
choice of a column of the same length packed with 5 ~m C18 material 
(Techsil). This column provided adeq uate resolution between these two 
compounds as is depicted in Fig. 2.11 and was subsequently used for a 
large proportion of the initial app lication of the HPLC method to the 
analysis of biological fluids. The high speed column proved to be less 
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FIGUR~ 2.11 Chromatograms of oleandomycin (1) and erythromycin (2) 
COLUMNS: A) 10 ~m Techsil 
B) 5 ~m Techsil 
MOBILE PHASE: 0.05M phosphate buffer/acetonitrile (50/50), pH 7.00 
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FIGURE 2.12 Chromatogram of oleandomycin (1) and eythromycin (2) 
COLUMN : Novapak 
MOBILE PHASE: 0.05 M phosphate buffer/acetonitrile (70/34), pH 7.00 
efficient than the 5 ~m C18 column probably due to the extra-column 
bandwidth broadening effects caused mainly by the relatively large 
detector cell volume of 8 ~L (Kratos detector) . The Novapak column 
provided the best peak shape and resolution of erythromycin and the 
internal standard, with the k' values being 4.0 and 3.1 respectively 
(Fig. 2.12) using chromatographic system 0 (Table 2.1). 
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By small adjustments in mobile phase composition, thi s method cou ld be 
adapted to biological fluid analysis with the internal standard being 
separated from early eluting biological fluid components. The retention 
of erythromycin and some of its derivatives and components are reported 
in Table 2.3 using the Novapak column (system D) (Tab le 2.1). 
TABL E 2.3 Retention times of erythromycin and var ious other 
macrol ides 
COMPOUND RETENTION k' TIME (min) 
OLEANDOMYCIN PHOSPHATE 2.8 3.1 
OES·N·METHYLERYTHROMYCIN 3. 0 3.3 
ERYTHROMYCIN (USP) 3.6 4.0 
ERYTHROMYC III STEARATE 3.6 4.0 
ERYTHROMYCIN B 7.0 7.7 
JOSAMYCIN 11.0 12.2 
ANHYOROERYTHROMYCIN 9.4 10.4 
ERYTHRALOSAMI NE 11.0 12.2 
lRYTHROMYC IN ENOL ETHER 20.0 22.0 
ERYTHROMYCIN ESTOLATE 44. 0 48.B 
ERYTHROMYCIN ETHYLSUCCINATE 50.0 55.6 
TRIACETYLOLEANOOMYCI N UNKNOWN 
COLUMN : Novapak 
MOBILE PHASE: 0.05 M phosphate buffer/acetonitrile (70/34) , pH 7.00 
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From Tabl e 2.3 it can be seen that this chromatographic system was 
ideally suited for the analysis of erythromycin and its components . The 
extremely long retention times of the two esters of erythromycin, 
erythromycin ethylsuccinate and estolate did not al low the direct 
application of this method to the analysis of these esters. Any attempt 
at decreasing the retention times of these compounds would have 
resulted in a shorter retention time for erythromycin making the 
application of this method to bio log ical fluid analysis impossible. The 
retention times for these esters on the non-end-capped C18 columns were 
considerably shorter. An assay procedure for the analysis of these 
compounds cou ld be developed using the high speed or, 5 ~m C18 columns 
used in this study with small changes in the mobile phase compos i tion. 
2.4.6 Evaluation of Column Packing Techniques 
Reverse phase columns packed by the method described, have been shown 
to be consistently comparable to similar commercially available columns 
at significantly reduced costs. The use of carbon tetrachloride as the 
slurry solvent and the time taken between the loading of the slurry and 
commencement of pressurization are vital to this technique. The 
constant degassing of the follow up-solvent (methanol) was an added 
precaution, as methanol is known to rapidly re-absorb oxygen after 
degassing (118). 
2.4.7 Effect of Flow Rate 
The optimum flow rate, as recommended by the manufacturers , for the 
Novapak column is 0.5 mL/min , which provided adequate separation 
between erythromycin and the internal standard at ambient temperature. 
An increase of flow rate in 0.1 mL increments provided comparable 
separation and improved peak shape leading to the choice of 1.0 mL/min 
as the optimum flow rate for this column. Changes in flow rate had a 
more dramat i c effect on t he efficiency of the high speed column. 
Flow rates below 2.0 mL/m in resulted in very poor peak shape and 
resolution between erythromycin and the internal standard (Fig. 2. 13 ). 
A flow rate of 2.0 mL/min was chosen as the optimum flow rate for the 
high speed co lumn as the backpressure of 3000 psi prohibited the use of 
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higher flow rates. In addition, from the typical Van Deemter curve for 
a column of these dimensions (Fig. 2.3) an increase in flow rate above 
2.0 mL/min would not be expected to increase column efficiency, but 
only to result in a decrease in analysis time. 
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FIGURE 2.14 The effect of column temperature on the separat ion of 
oleandomycin (1) and erythromycin (2) A) 25°C 
B) 35°C 
COLUMN: 5 ~m Techsil 
MOBILE PHASE: 0.05 M ~hosphate buffer/acetonitrile (50/50), pH 7.00 
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2.4.8 The Effect of Column Temperature 
The improvement in column efficiency, as represented by the peak shape 
and resolution of erythromycin from other macrolide antibiotics has 
been previously reported (143,149) . The effect of an elevation of 
column temperature from ambient temperature (20-25°C) to 45 °C on the 
resolution of erythromycin and the internal standard when using the 
5 ~m C18 column is depicted in Fig 2.14. The Novapak column provided 
adequate resolution between erythromycin and the internal standard at 
room temperature. However, in the application of this method to the 
analysis of biological fluids, a column tempe rature of 35 °C helped in 
assuring the separation of the internal standard from the ear ly eluting 
biological fluid components. 
2.4 .9 Guard Column Choice 
The use of the Rheodyne guard column fitted with a C18 cartridge 
resulted in an increase in retention times with associated decreases in 
peak shape and sens itivity for erythromycin and the internal standard. 
Erythromycin did not elute 
with a C18 cartridge, 
(Fig. 2.15). This was 
at all when using the Guard - Pak un it fit ted 
prior to the Novapak analytical column 
most probably due to the activity of the 
residual silanol groups on the pellicular guard column packing 
substrate when using a mobile phase optimized for the highly end 
capped packing substrate of the analytical column. The use of cyano 
(CN) or glass bead cartridges had a minimal effect on the 
chromatography. The mean peak height ratios of erythromycin and 
internal standard for three urine samples at five different 
concentrations were unchanged after chromatography both with and 
without a glass bead guard column in-line (Table 2.4). 
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FIGURE 2.15 Chromatogram of erythromycin (1) using a Guard-Pak 
guard column unit A) C18 Cartridge B) CN Cartridge 
COLUMN : Novapak 
MOBILE PHASE: 0.05 M phosphate buffer/acetonitrile (70/30), pH 7.00 
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TABLE 2.4 The effect of a glass bead guard column on the peak height 
ratios of extracted urine samples 
CONCENTRATION OF 
URINE SAMPLE "g/mL 
10.00 
15.00 
20.00 
25.00 
50.00 
(0.5 mL Sample) 
2.4.10 Solvent Degassing 
MEAN PEAK HEIGHT RATIO (n,3) 
ERY1HROMYCIN/INTcRNAL STANDARD 
Without Guard Column With Guard Column 
0.93 0.93 
1.35 1.30 
1. 70 1. 70 
2.20 2.13 
1. 92 1.90 
Although the mobile phase was degassed before use, it was found that 
during lengthy analysis, the baseline remained more stable to drift and 
short term baseline noise when an in-line vacuum solvent degasser was 
used. Within-run degassing by periodic ultrasonication was initially 
used but was found to cause sudden baseline drifts. This has 
previously been reported by Bakalyar et aZ. (118). 
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2.5 CONCLUSIONS 
The high performance liquid chromatographic methods using the 5 ~m 
Techsil and Novapak columns described in this chapter compare 
with the established HPLC method of Tsuji and Kane (145) 
analysis of erythromycin in pharmaceutical dosage forms. 
favorably 
for the 
The Novapak column, which yielded excellent peak shape at ambient 
temperatures, would be expected to have a considerably longer 
ana lytica l life than the column used by Tsuji and Kane ( 145) which was 
operated at 70°C. Although the retention time for erythromycin was 
shorter on the Novapak column (3.6 min vs 9.0 min), this column could 
not be used for the analysis of the esters of erythromycin due to the 
extremely long retention times recorded for these compounds 
(Table 2.3). The method developed using the 5 ~m Techsil column could 
be adapted for th i s purpose. 
The optimization of mobile phase components and operating conditions to 
allow the utilization of a U.V. detection wavelength of 200 nm was not 
of any particular importance in the analysis of erythromycin in vitro, 
as sensitivity is seldom a major concern in these studies. It did, 
however, provide the necessary sensitivity for the development of an 
HPLC technique using U. V. detection for the analysis of erythromycin in 
serum and urine at the concentrations found in humans after the 
administration of oral dosage forms. 
The comprehensive test ing of various U.V. detectors at the conditions 
of their envisaged deployment, proved to be invaluable in the final 
selection of the Kratos detector for this analysis. 
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CHAPTER THREE 
DETERMINATION OF ERYTHROMYCIN IN BIOLOGICAL FLUIDS 
3.1 INTRODUCTION 
Microbiological assay methods, as previously described, have been used 
for the majority of studies involving the analysis of erythromycin in 
biological fluids. These methods, while being sufficiently sensit ive, 
lack the specificity necessary for detai led pharmacokinetic studies. 
In 1969 Stephens et al. (63) reported a paper chromatographic technique 
for the separation of erythromycin from the inactive propionate ester 
after the administration of erythromycin estolate. This method 
utilizes a microbiological end-point (bio-autography) and hence suffers 
from similar specificity problems to that of convent ional 
microbiological methods. This method was later adapted to thin layer 
chromatography - bioautography by Easterbrook and Hersey (150). 
A chemical assay for the analysis of erythromycin and erythromycin 
propionate was reported by Tserng and Wagner (151). In th is method, 
serum samples were adjusted to pH 6.00 for the etherea l extraction of 
the ester and to pH 9.00 for extraction of erythromycin base. The 
extracts were then measured fluorimetrically after complexation with a 
fluorescent dye (Tinopal G.S.). 
Tsuji (152) described an HPLC technique based on the same detection 
method as Tserng and Wagner (151) for the analysis of erythromycin, 
erythromycin ethylsucc i nate and some of their components/degradation 
products in serum. A 25 cm C18 column was used at a temperature of 
70°C, following an extensive liquid - liquid extraction. A relative ly 
complex post-column derivatization and extraction procedure preceded 
fluorimetric detection, necessitating the use of expensive and 
complicated apparatus. In addition, erythromycin was not well resolved 
from its metabolites/degradation products (presumed to be 
erythralosamine and anhydroerythromycin) present in human serum after 
oral administration of an erythromycin ethylsuccinate suspension. This 
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method has not been used in any published studies to date. 
A recent paper by Chen and Chiou (9) described the HPLC analysis of 
erythromycin in biological fluids using electrochemical detection 
following separation on a C18 column. A novel dual electrode 
electrochemical detector operated in the oxidative screen mode was 
used. This procedure was reported as being extremely sensitive, 
allowing the use of small sample aliquots (0.1 to 1.0 mL). Serum 
samples were extracted using the same ether extraction as reported 
earlier (151) for serum and a simple precipitation step for urine. 
However, in order to reduce background currents and enhance detector 
stability, it was necessary to maintain the HPLC system in operation 
continuously even when not in use. Furthermore, the choice of 
erythromycin B as internal standard may lead to anomalies during 
pharmacokinetic studies since varying amounts of this compound are 
usually present in batches of raw material (2,122). Using this 
chromatographic method, two metabolites/degradation products 
(anhydroerythromycin and an unidentified compound), were detected in 
serum and urine of dogs after oral administration of erythromycin. 
A further recent report by Duthu (99), using the same detector system 
as Chen and Chiou (9), described the analysis of erythromycin in serum 
only, using a similar extraction procedure but with different 
chromatographic conditions. A diphenyl reverse phase column was used, 
which was reported to cause less peak tailing than C8 or C18 columns. 
A drug-related peak was observed in serum of human subjects after oral 
administration of a suspension of erythromycin but was absent in serum 
of subjects receiving an enteric coated erythromycin product. This 
compound was tentatively identified as the internal spiroketal of 
erythromycin. These two methods (9,99) are extremely sensitive and 
will no doubt find widespread use in the analysis of erythromycin in 
serum and urine. However, problems associated with the use of 
electrochemical detectors in general, may limit their widespread 
acceptance. The comparison of HPLC methods using electrochemical and 
U.V. detection for the analysis of erythromycin and its components is 
extensively discussed in Section 4.3.6. 
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The analysis of compounds in biological fluids by chemical 
usually necessitates a sample preparation stage (153). 
methods 
Thi s is 
particularly important for non-chromatographic techniques in which 
se lectivi ty is predominantly attained by the meticu lous elimination of 
possible contaminants by extensive sample work-up procedures (153). 
The increased selectivity afforded by HPLC has limited the extent of 
this sample preparation stage in the majority of analyses. A simple 
protein precipitation step performed by the addition of a strong acid, 
or an alcoho l, followed by centrifugat ion, normally suffices when the 
concentrat ion of the compound is sufficiently high and the detection 
. method sufficiently se lective (154). Where extra sample clean-up prior 
to chromatography has proved necessary, liquid 
systems have predominantly been used (154). 
- liquid extraction 
These extraction 
procedures rely on the selective separation of the unionized compound 
into a water immiscible solvent by the adjustment of the samp le pH. The 
sample is then taken to dryness 
for chromatographic analysis, 
concentration procedure (153). 
and reconstituted in a su itable solvent 
providing both a sample clean-up and 
Various other extraction procedures such as thin layer chromatography, 
ion-pair formation and solid phase extractions have been used for this 
purpose (153,154). 
In solid phase extractions, the compound of interest is se lectively 
adsorbed onto the extraction column matrix which is then washed to 
remove interfering compounds. The compound of interest is then eluted 
from the extraction column into a collecting tube by a further solvent 
mixture. Many different solid phases have been used, such as charcoal, 
silica, alumina, ion exchange resins and X-AD-2 (a hydrophobic 
polystyrene resin) (153). Recently, extraction columns packed with the 
same solid phases as those used in conventiona l HPLC have become 
available, which have extended the use of this technique. 
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The main advantages of solid phase extraction systems over liquid 
liquid extraction methods are as follows. 
1) Cleaner extracts are obtained, 
( 153 , 155) . 
due to increased selectivity 
2) Sample losses due to emulsion formation do not occur (154). 
3) Smaller volumes of solvents are used resulting in decreased 
analysis costs (156). 
4) Less hazardous solvents are used (156). 
6) Compounds which are unstable at the extreme pH ranges needed 
for their extraction into organic solvents may be extracted 
using solid phase techniques (117). 
The principle disadvantage of these methods is the possibility of 
permanent adsorption losses of compounds with high affinity for the 
stationary phase, resulting in decreased sample recoveries (153). 
When comparing the ability of different extraction procedures to remove 
interfering endogenous serum and urine components prior to 
chromatography, it is useful to have some indication of the amount of 
the original biological sample and hence potential interference, that 
has been loaded onto the column. A term, the "percentage sample 
loaded" has been used for this purpose throughout this study and is 
defined as follows: 
The percentage sample loaded, is the percentage of the final 
reconstitution volume which is loaded onto the column. The original 
sample volume (i.e. volume of serum or urine to be analysed), must "be 
constant for all extractions compared using this parameter. 
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3.2 DEVELOPMENT OF AN EXTRACTION METHOD FOR ERYTHROMYCIN FROM 
SERUM AND URINE 
3.2.1 Experimental 
3.2.1.1 Sample Preparation 
Aqueous solutions of erythromycin 
12.00 ~g/mL) were prepared as 
(0.50 ~g/mL) and oleandomycin (3.00-
in Section 2.3.1. During these 
developmental stages, spiked serum and urine samples of different 
concentrations were prepared by the addition of appropriate amounts of 
the aqueous solutions of erythromycin to drug free serum or freshly 
collected urine. The concentration ranges of both serum and urine 
varied between 1.00 and 10.00 ~g /mL depending on the stage of the 
method development. Transfer pipettes were used for the dispensing of 
0.5 and 1.0 mL aliquots while a programmable automatic pipette 
(Hamilton Microlab-P) was used for the addition of aliquots between 
20.0 and 100.0 ~L. 
3.2.1.2 Chromatographic Conditions 
HPLC System As in Section 2.3.2 
Column and mobile phase Systems A, B, D, E (Table 2.1) 
Flow rate 1.0 mL/min 
Pressure and temperature Table 2.1 
Detection wavelength U.V. 200 nm (Kratos detector) 
Sensitivity 0,01 AUFS 
Recorder input 10 mV 
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3.2.1.3 Solid Phase Extraction System 
A "Baker - 10" Extraction system (J.T. Baker Chemical Co.) was used 
which consisted of the following components. 
FIGURE 3.1 "Baker 10" solid phase extraction system 
. . 
• 
1) "Baker 10" vacuum mani fold 
2) Removable lid 
3) Disposable extraction columns containing 40 ~m C18 material (1 mL capacity) 
4) Sample reservoirs (15 mL) 
5) Collection rack 
6) Glass collection tubes (2 mL) 
7) Vacuum trap 
8) Model A2-S Aspirator (Rikakikai Co. Ltd.) 
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3.2.1.4 Additional Equipment 
1) Culture tubes 15mL (Kimble) 
2) WISP limited volume inserts (Waters Associates) 
3) Model 701SN Analytical syringe (Hamilton-Bonaduz) 
4) N-Evap analytical evaporator (Organomation Associates) 
5) Transfer pipettes (Brand) 
6) Microlab~P automatic pipette (Hamilton-Bonaduz) 
7) An Apple II micro-computer was used for the linear least 
squares regression analysis 
3.2.1.5 General Extraction Method 
were developed, the first for the initial Two main procedures 
developmental studies using aqueous sample loads and the second for the 
extraction of spiked serum and urine samples. 
In the first method, the extraction column was washed successively with 
methanol (2.0 mL), water (2.0 mL) and acetonitrile /water (50/50-
2.0 mL) with a vacuum of between 0 and 10 mm Hg being maintained. 
The sample (0.1 to 1.0 mL) was then loaded onto the ext raction column 
followed by a wash of acetonitrile/water (70/30 - 2.0 mL), after which 
the extraction column was allowed to go to dryness. The vacuum was 
then broken, in order to place the collection tubes in pOSition, and 
then re-applied to assist in the elution of the compounds of interest 
from the extraction columns with three 500 ~L ali quots of 
acetonitrile/0.05 M phosphate buffer (50/50), pH 7.00. The 
concentration of erythromycin in the eluate (1.5 mL) was usually 
sufficient and did not require a further concentration step prior to 
chromatography. Where necessary, the eluate was taken to dryness under 
a stream of nitrogen at 40°C and reconstituted to 500 ~L with water. 
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The relative efficiencies of the various eluting solvent systems and 
sequences used were compared by quantification of the peak heights 
obtained from a calibration curve. The recoveries were calculated by 
comparison of the amount of erythromycin eluted, to the original amount 
of erythromycin loaded onto the extraction column. 
For the analysis of serum and urine, the initial wash cycle was changed 
to acetonitrile (3.0 mL) followed by water (3.0 mL). One millilitre of 
serum or urine was precipitated with 1.0 mL acetonitrile and 
centrifuged at 1 600xg, after which the supernatant was transferred to 
a culture tube containing 4.0 mL water. This mixture was then loaded 
onto the pre-treated extraction column with the aid of a sample 
reservoir. 
The extraction column was washed with water (5.0 mL) followed by 
acetonitrile/water (50/50 - 5.0 mL), after which it was allowed to go 
to dryness under vacuum. The drug was then eluted from the extraction 
column with two successive 500 ~L volumes of acetonitrile/O.OS M 
phosphate buffer (50/50), pH 7.00. The eluate was taken to dryness in 
a rotary vacuum centrifuge (Savant) and reconstituted as follows: 
Twenty microlitres of water were added to each dried extract followed 
by vortex mixing for 1 min. On addition of 2S.0 ~L acetonitri le, two 
layers formed, which were separated after vortex mixing by 
centrifugation at 1 600xg for 2 min . Approximately 1S.0 - 20.0 ~L of 
the upper (acetonitrile) layer were transferred using an analytical 
syringe to a WISP limited volume insert for injection into the 
chromatographic system . 
This extraction technique was later adapted for the extraction of 
2.0 mL serum samples by the addition of 2.0 mL acetonitrile followed 
by centrifugation and dilution of the supernatant with 8.0 mL water. 
The internal standard (oleandomycin phosphate) was added either in the 
acetonitrile used for sample precipitation, or as a 2S0 or SOO ~L 
aliquot immediately prior to sample precipitation. 
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3.2.2 Results and Discussion 
3.2.2.1 Choice of Extraction Technique 
A highly selective extraction procedure was necessary for the analysis 
of erythromycin in biological fluids using the HPLC method discussed in 
the previous chapter, due to the low and relatively nonspecific U.V. 
wavelength employed (105,157) the high detector sensitivity and the 
extensive sample concentration needed to obtain the desired sensitivity 
limits (0.25 ~g /mL serum, 5.00 ~g /mL urine). 
A solid phase extraction technique was chosen for this purpose as it 
was felt that such a system would provide the most simple yet efficient 
extraction procedure. Octadecylsilane extraction columns were chosen as 
the retention of erythromycin on this solid support was well understood 
after the development of the HPLC technique previously discussed. 
3.2.2.2 Extraction of Aqueous Samples 
During the development of an HPLC method for the analysis of 
erythromycin, it was noticed that erythromycin did not elute from a C18 
column if the mobile phase did not contain a suitable buffer component 
(Section 2.4.4). Similar results were found when aqueous samples of 
erythromycin were loaded onto C18 extraction columns. A mixture of 
acetonitrile/0.05 M phosphate buffer (50/50) was the only solvent 
combination which eluted the drug from the extraction column 
(Fig. 3.2). Other solvents tested included acetonitrile, methanol, 
water, phosphate buffer, acetonitrile/water and methanol/water. 
The initial wash cycle of methanol (2.0 mL), water (2.0 mL) and 
acetonitrile/water (50/50 - 2.0 mL) was found to be necessary in order 
to both condition and clean the extraction column prior to extraction. 
A pure methanol wash was necessary before loading the ext raction column 
with aqueous samples. The polar organic solvent is reported to be 
necessary in order to "activate" the non-polar solid support prior to 
contact with aqueous samples (156). Elution of the drug was found to be 
more efficient when the same volume of eluting solvent was applied in 
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FIGURE 3.2 Chromatogram of an extraction of an aqueous sample of 
erythromycin (1) in which the drug was eluted with 
A) acetonitrile/water (50/50) 
B) acetonitrile/0.05 M phosphate buffer (50/50) 
COLUMN: 10 ~m Techsil 
MOBILE PHASE: 0.05 M phosphate buffer/aceton it ri le (50/50), pH 7.00 
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smaller aliquots. with the extraction column being allowed to go to 
dryness between each elution. When using an acetonitrile/0.05 M 
phosphate buffer (50/50). pH 7.00 eluting solvent. a single 500 ~L 
volume eluted 72% of the drug whereas a serial wash of 300 and 200 ~L 
eluted 82% of the drug. Similar results were obtained by Good and 
Andrews (158) for the extraction of benzodiazepines in serum using the 
same extraction columns. A total volume of 1.0 ml of this eluting 
solvent was chosen as being the ideal volume of eluting solvent. as it 
eluted 95% of the drug. A change in composition of the eluting solvent 
to acetonitrile/0.05 M phosphate buffer (70/30). pH 7.00 had no effect 
on the amount of erythromycin eluted from the extraction column. with 
500 ~L of this solution eluting 80% of the drug. 
Oleandomycin. the internal standard. performed similarly to 
erythromycin on the C18 extraction columns . It did not elute from the 
extraction column with an acetonitrile/water wash while it was eluted 
with a mixture of acetonitrile and 0.05 M phosphate buffer. 
3.2.2.3 Extraction of Serum and Urine Samples 
The major problem in the adaptation of the basic method described for 
aqueous samp les to the analysis of serum samples. was the precipitation 
of serum proteins when loaded onto the pre-washed extraction columns. 
This led to clogging of the extraction columns even when using smal l 
serum aliquots (250 ~L). The problem was alleviated by the pre-
precipitation of 1.0 mL serum samples with 2.0 mL acetonitrile/water 
(50/50) prior to loading. However. when these samples were washed with 
a mixture of acetonitrile/water. the necessity of which is described 
later. erythromycin eluted from the extraction column (Fig. 3.3). This 
was possibly due to the eluting power of the mixture of the 
acetonitrile and endogenous ions present in the serum sample. The 
precipitated sample was then diluted with 4.0 mL of water after 
centrifugation and immediately prior to loading onto the extraction 
column as it was known that a pure water wash did not elute the drug 
from these samples (Fig.3.3). Similarly the subsequent 
acetonitrile/water (50/50) wash did not elute the drug from samples 
loaded in this manner (Fig. 3.3). 
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FIGURE 3.3 Chromatogram of an extraction of a pre-precipitated serum sample containing 
erythromycin (1) after the extraction column had (A) been washed with 
acetonitrile/water(50/50) and (B) been washed with pure water. In 
chromatogram (C) the same pre-precipitated sample had been diluted with 
4.0 mL water prior to loading and the extract ion column washed with 
acetonitrile/water (50/50). 
COLUMN: 10 ~m Techsil 
MOBILE PHASE: 0.05 M phosphate buffer/acetonitrile (50/50), pH 7.00 
I 
I-
U 
W 
-, 
Z 
" 
" 
78 
Although a water wash did not elute the drug from the extraction 
column, it did not result in a clean final extract which was 
sufficiently free from interference from endogenous serum components. 
For this purpose it was found that an acetonitrile/water wash 
containing at least 50% acetonitrile was essential, as chromatograms of 
samples washed with a 10% acetonitrile/water wash were not clean enough 
for quantification of the erythromycin peak (Fig. 3.4). The effect of 
urine components on the chromatograms of extracts is depicted in 
Fig.3.5. In this experiment, an aqueous sample of erythromycin was 
extracted along with identical samples to which 0.25, 0.5 and 1.0 mL 
aliquots of urine were added. The resulting chromatograms show 
increased interference which may be directly related to the amount of 
urine added. Five millilitre acetonitrile/water (50/50) washes were 
found to clean the samples sufficiently and were used in all 
subsequent analysis. 
3.2.2.4 Concentration of the Elution Volume 
The initial extraction procedure used, in which samples were 
reconstituted to 500 ~L with mobile phase, yielded quantifiable 
chromatograms for the analysis of serum and urine samples of 
erythromycin in the concentration range 50.00-100.00 ~g/L. The range 
of concentrations found after administration of dosage forms of 
erythromycin is however, considerably lower (0.25-5.00 ~g /mL for serum 
and 5.00-50.00 ~g /mL for urine - Table 1.2). The dried extracts (1.0 mL 
Serum) were then reconstituted in 100 ~L mobile phase in order to 
provide a potential five fold increase in sensitivity. On injection of 
various volumes of these samples, it was found that the interference 
from serum or urine components became a serious problem when the 
injection volume was greater than 10.0-20.0 ~L (Fig.3.6). This 
represented a percentage sample load for 1.0 mL samples of 10-20%. 
It was also established that the chromatographic interference was not 
only due to endogenous compounds but was also due to t he buffer 
component which had been concentrated. One millilitre of a mixture of 
erythromycin and oleandomycin in acetonitrile was taken to dryness and 
reconstituted in 50.0 ~L acetonitrile of which 10.0 ~L were then 
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FIGURE 3.4 Chromatogram of a 1.0 mL serum extract containing 
erythromycin (1) after elution with 2.0 mL 0.05 M 
phosphate buffer/ acetonitrile (50/50). The 
extraction column had been washed with 2.0 mL 
A) acetonitrile/water (50/50) 
B) acetonitrile/water (10/90) 
COLUMN: 5 ~m Techsil 
MOBILE PHASE: 0.05 M phosphate buffer/acetonitrile (50/50), pH 7.00 
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F[GUR~ 3.5 Chromatogram of an aqueous extract of oleandomycin (1) 
and erythromycin (2) to which 
A) No urine was added 
B) 0.25 mL urine was added 
C) 0.50 mL urine was added 
D) 1.00 mL urine was added 
COLUMN : Novapak 
MOBILE PHASE : 0.05 M phosphate buffer/acetonitrile (70 / 34), pH 7.00 
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FIGURE 3.6 Chromatogram of a blank serum extract (1.0 mL) without 
the phase separation step . The percentage samples 
loaded were A) 10% 
B) 20% 
C) 30% 
COLUMN: 5 ~m Techsil 
MOBILE PHASE; 0.05 M phosphate buffer/acetonitrile (50/50), pH 7.00 
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injected onto the column. Figure 3.7 compares the chromatogram of such 
a sample, to that of an identical sample to which 300 ~L of 0.05 M 
phosphate buffer were added and treated as above. The increase in the 
number of interfering peaks caused by the buffer component is clearly 
evident. The amount of buffer added, represented the amount of buffer 
present in 1.0 mL of a acetonitrile/buffer elution solvent (70/30). 
Numerous attempts were made to separate erythromycin from the aqueous 
phase containing the buffer components, into an organic phase. Salting 
out of the acetonitrile and buffer layers immediately after elution 
with both NaCl and Na2S04 was troubled by the carryover of the salts 
into the organic solvent, which inhibited the reconstitution of the 
dried extracts into small solvent volumes. The separation of 
erythromycin into ether, carbon tetrachloride, chloroform, cyclohexane, 
isooctane and pentane, with the pH adjusted with sodium carbonate 
(151), proved unsuccessfu l . An attempt to differentially freeze the 
acetonitrile (freezing pOint -43°C) and aqueous components of the 
eluate also failed. 
3.2.2.5 Reconstitution of Samples 
The composition of the reconstitution solvent proved to be the key to 
increasing the percentage sample load and hence sensitivity of t he 
assay. Two distinct layers formed on addition of 50 .0 ~L acetonitrile/ 
0.05 M phosphate buffer (50/50) to dried extracts due to the "salting 
out" (117) of t he organic layer by the high concentration of buffer 
salts present in the aqueous layer. Injection of these separate layers 
into chromatographic system E (Table 2.1), after extraction of a 
2.0 mL spiked serum sample (0.25 ~g/mL) showed that erythromycin was 
present in the upper (acetonitrile) layer and was well resolved from 
the endogenous serum components, while the aqueous layer contained many 
co-eluting compounds which made the identification of the drug 
impossible (Fig.3.8). 
Initial attempts at consistently separating the two layers of this 
mixture with a pasteur pipette were not successful as the relatively 
large pipette tip caused some disturbance and hence mixing of the two 
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FIGURE 3.7 Chromatogram of a mixture of oleandomycin (1) and 
erythromycin (2) in (A) acetonitrile and 
(B) acetonitrile/buffer (70/30) 
after being taken to dryness and reconstituted in 
acetonitrile (50.0 ~L) 
COLUMN 5~m Techsil 
MOBILE PHASE: 0.05 M phosphate buffer (50/50), pH 7.00 
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FIGURE 3.8 Chromatogram of (A) the upper layer (acetonitrile) and 
(B) lower layer (aqueous) after reconstitution of a 
2.0 mL serum extract containing erythromycin (1) 
with water (20.0 ~L) and acetonitrile (25.0 ~L) 
COLUMN : Novapak 
MOBILE PHASE: 0.05 M phosphate buffer/acetonitrile (70/30), pH 7.00 
INJECTION VOLUME : 5 ~L 
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layers. Cleaner extracts were obtained when an analytical syringe with 
a narrow needle was used. 
This method of sample reconstitution and solvent separation enabled the 
injection of between 5.0 and 10.0 ~L of the 25.0 ~L acetonitrile volume 
after extraction serum samples (i.e. a 20 to 40% sample load) with 
sufficient separation between erythromycin, the internal standard and 
the interfering peaks, to allow successful quantification of these 
compounds. The distribution of erythromycin and oleandomycin between 
the two phases was studied by the addition of appropriate amounts of 
the drugs to 1.0 mL acetonitrile/0.05 M phosphate buffer (50/50). The 
samples were then taken to dryness and reconstituted as described. 
Samples from each layer where analysed by HPLC and the amount of drug 
in each phase compared. Table 3.1 shows the percentages of the two 
drugs present in the aqueous phase compared to the acetonitrile layer. 
TABLE 3.1 The distribution of erythromycin and oleandomycin between the 
two layers formed on reconstitution of extracts. 
ERYTHROMYCIN OLEANOOMYCIN 
SAMPLE CONCENTRATION PERCENTAGE DISTRIBUTION PERCENTAGE DISTRIBUTION 
. g/mL (n~3) AQUEOUS/ACETONITRILE AQUEOUS/ACETONITRILE 
LAYER LAYER 
0.50 14.0 16.0 
1.00 16.6 13.5 
2.50 17.0 18.0 
5 .~ 18.0 14.0 
10.UO 11.0 16.0 
20.00 10.3 15.0 
Mean Value 14.5 15.4 
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The mean percentage of erythromycin remaInIng in the aqueous 
14.5%. Due to the larger volume of the acetonitr i le layer 
phase was 
(25 . 0 vs 
20.0 ~L) and the possible contamination of the aqueous layer with some 
of the erythromycin rich acetonitrile layer, the estimation of the 
amount of erythromycin present in the aqueous layer was presumed to be 
slightly exaggerated. It was therefore assumed that a 10 to 15% range 
would be a more accurate estimat ion of the amount of erythromycin 
remaining in the aqueous layer. 
3.2.2.6 Re-Use of , Extraction Columns 
The extraction columns were found to be re-usable. Six spiked urine 
samples at two different concentrations were extracted as in section 
3.4.1.3., after which a further six samples were extracted using the 
same extraction columns. There were no significant differences in peak 
height ratios or relative standard deviations between the two 
extractions at either concentration. These results are summarized in 
Table 3.2. The chromatograms from both series of extractions were 
similar, indicating that there was no accumulation of contaminants. 
TABLE 3.2 Within-run precision after re-use of extraction columns 
URINE MEAN PEAK HEIGHT RATIOS (n ~ 3) RE LATIVE STANDARD 
CONCENTRATION ERYTHROMYCIN/INTERNAL STANDARD DEVIAT ION 
~g/mL 
1st EXTRACTION 2nd EXTRACTION 1st EXTRACTI ON 2nd EXTRACTION 
10 .00 0.69 0.73 3.3% 1.51 
20.00 1.39 1.W 3. 0% 2.71 
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3.3 ANALYSIS OF ERYTHROMYCIN iN SERUM 
3.3.1 Experimental 
3.3.1.1 Sample Preparation 
An erythromycin serum stock solution (5.00 ~g/mL) was prepared as 
follows: 
Twenty five milligrams of erythromycin were dissolved in 50.0 mL water 
and 0.5 mL of this solution was made up to 50.0 mL with blank serum. 
Appropriate dilutions of this stock solution were then made. 
The internal standard stock solution was prepared by dissolving 24.0 mg 
oleandomycin phosphate in 1.0 mL acetonitrile which was then made up to 
100.0 mL with water. The internal standard solution (12.00 ~g/mL) was 
then prepared by diluting 5.0 mL of this stock solution to 100.0 mL 
with water. 
3.3.1.2 Chromatographic Conditions 
HPLC System 
Column 
Mobile phase 
Flow rate 
Pressure and temperature 
Detection wavelength 
Sensitivity 
Recorder input 
As in Section 2.3.2 
Novapak 
0.05 M phosphate buffer/acetonitrile 
(70/30), pH 7.00 (System E, Table 2.1) 
1.0 mL/min 
Table 2.1 
U.V. 200 nm (Kratos detector) 
0.005 AUFS (Kratos detector 0.01 AUFS 
coupled to the Spectrum filter on a x2 
amplification setting and a 0.01 sec 
filter setting) 
10 mV 
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3.3.1.3 Extraction Procedure 
Two millilitres of serum were mixed with 250 ~I of the internal 
standard solution. Addition of 1.0 mL acetonitrile followed by vortex 
mixing for 1 min and centrifugation for 5 min at 1 600xg resulted in 
deproteinization of the serum sample. The supernatant was transferred 
to a culture tube containing 8.0 mL water for direct loading onto a 
1.0 mL disposable C18 extraction column, which had been pre-washed 
under 10-15 mm Hg vacuum, by successively passing 3.0 mL acetonitrile 
and 3.0 mL water through each. The diluted sample was then added to 
the extraction column with the aid of a sample reservoir. The 
extraction column was washed with 5.0 mL water and then 5.0 mL 
acetonitrile/water (50/50) with vacuum maintained until dry. 
Erythromycin and the internal standard were eluted into tapered 
collection tubes with two successive 500 ~L aliquots of 
acetonitrile/0.05 M phosphate buffer (50/50). The sample was then taken 
to dryness in a rotary vacuum centrifuge. The residue in the 
collection tube was reconstituted in 20.0 ~L water and vortexed for 1 
min. After addition of 25.0 ~L acetonitrile the mixture was vortexed 
and then centrifuged for 1 min at 1 600xg. Five microlitre a liquots of 
the top layer were injected onto the column. 
3.3.1.4 Cal ibration Curve 
The serum stock solution was diluted to yield four different 
concentrations, the stock solution itself providing the fifth. 
Concentrations ranged from 0.25 to 5.00 ~g/mL and each concentration 
was assayed in triplicate. The calibration curve was constructed by 
plotting the ratio of the peak height of erythromycin to that of the 
internal standard, versus the respective erythromycin concentration. A 
straight-line fit of the data was made by least-squares linear 
regression analysis. 
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3. 3. 1.S Precis ion 
Within- run precision was assessed by extracting six spiked serum 
samples each at the upper and lower limits of the concentration ranges 
studied (O.SO and 2.00 ~g/mL). 
3.3. 1. 6 Extraction Efficiency 
For this study, in which the analytical recovery of erythromycin from 
serum was assessed, spiked serum samples were assayed in triplicate at 
three different concentrations . All samples were extracted as 
previously described except that the internal standard was incorporated 
into the 2S.0 ~l aliquot used in the final reconstitution and phase 
separation step and was thus not carried through the extraction 
procedure . 
Standard solutions of erythromycin corresponding to those extracted 
above, were made up in 1.0 mL of acetonitrile/ O. OS M phosphate buffer 
(SO/SO) and were taken to dryness in a rotary vacuum cent rifuge. These 
samples were then reconstituted as for the serum samples with the 
internal standard being added in the 2S.0 ~L acetonitrile al iquot. To 
determine the percentage recovery, the ratios obtained from the serum 
extracts were compared to those resulting from the relevant standard 
solutions of equivalent concentrations. 
3.3.2 Resu l ts and Discussion 
3.3.2.1 Linearity and Calibration Curve 
Linearity was established for the range of concentrations studied 
(0.2S- S.00 ~g/mL). The curve had a slope of 0.029S, a y-intercept of 
0.2938 with a correlation coefficient of 0.9997. The calibration curve 
for erythromycin in serum is shown in Fig.3.9. Chromatograms of a blank 
serum extract and 
internal standard 
a serum extract containing erythromycin and 
are depicted in Fig . 3.10. The retention time 
for erythromycin was 6.2 min and that of the internal standard 4.2 min. 
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FIGURE 3.9 Calibration curve of erythromycin in serum 
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TABLE 3.3 Within-run precision study on serum assay 
SPIKED CONCENTRAT ION ~IEASUREO (,g/mL) 
CONC 
SAMPLE NUMBER 
(,g/mL) 2 3 4 5 6 MEAN (SO) R.S.O. 
0.50 0.49 0.48 0.52 0.53 0.52 0.50 0.51 (0.02) 3.92% 
2.00 2.02 1. 94 1.98 2.00 2.01 2.01 1.99 (0.03) 1.50% 
TABLE 3.4 Analytical recoveries of erythromycin in serum. 
SERUM % RECOVERY 
CONC 
(,g/mL) 2 3 MEAN (SO) R.S .O. 
0.50 85.0 89.6 79 .2 84.6 (5 .2) 6.2% 
1.00 82.8 76.7 82 .8 80.8 (3 .5) 4.4% 
2.00 85.3 79.9 80 .0 81.7 (3 .1 ) 3.8% 
MEAN PERCENTAGE RECOVERY (n"9) 82.4 (3 .9) 4.7% 
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FIGUR~ 3.10 Chromatogram of (A) a blank serum extract (2.0 mL) and 
(B) a serum extract (2.0 mL) containing 
oleandomycin (1) and erythromycin (2) 
COLUMN : Novapak 
MOBILE PHASE: 0.05 M phosphate buffer/acetonitrile (70/30), pH 7.00 
INJECTION VOLUME : 5 ~L 
ERYTHROMYCIN CONCENTRATION : 1.50~g/mL 
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3.3.2.2 Precision 
Results of the within-run precision 
Table 3.3. Relative standard deviations 
study are 
(RSD) at both 
depicted 
the upper 
in 
and 
lower concentration limits fall within the accepted limits for drug 
determinations. The method, as indicated by the above results was 
found to be reproducible. 
3.3.2.3 Extraction Efficiency 
Table 3.4 shows the analytical recoveries of erythromycin in serum. 
The mean recovery value of 82.4% obtained for serum, does not take into 
account the 10-15% of the drug remaining in the aqueous phase (Section 
3.2.2.5.). The overall recovery values may thus be adjusted by 10-15%. 
This 10-15% loss due to the final phase separation step was considered 
unimportant since the resulting extract enabled a percentage sample 
load of 30-40% from 2.0 mL serum samples which was free from sample 
interference. The limit of sensitivity was thus increased by 
approximately 6 to 8 times compared to extracts omitting this step, 
from which a maximum percentage sample load of only 10-15% was possible 
for 1.0 mL serum samples (Section 3.2.2.3.) due to extensive 
interference from other sample components. 
3.3.2.4 Sensitivity and Detection Limits 
Under the conditions of this assay and based on a minimum signal to-
noise ratio of 3, the detection limit for erythromycin in serum was 
0.25 ~g/mL. The detection li mit was increased where necessary by the 
use of a larger injection volume, which was associated with a slight 
increase in the interference from serum components. 
3.3.2.5 Stability of Samples on Storage 
Serum samples (1.00 ~g/mL) were found to be stable for 1 month at 4°e 
(95.0%, n=3). However, similar serum samples (1.00 ~g/mL) stored for 
1 month at -10 o e suggested that some degradation may have occurred 
(85.0%, n=3). The absence of any degradation products, suggested that 
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the low concentrations obtained may have been slightly in error. 
Erythromycin has been reported as being stable for three months in an 
acetonitrile solution when stored at -10DC (9) but only for 1 week at 
4DC (7). Samples containing higher concentrations of erythromycin were 
used in further studies on the stability of erythromycin in urine 
samples, in order to facilitate the detection of any possible 
degradation products. 
3.4 ANALYSIS OF ERYTHROMYCIN IN URINE 
3.4.1 Experimental 
3.4.1.1 Sample Preparation 
An erythromycin urine stock solution (50.00 ~g/mL) was prepared as 
follows: 
Twenty five milligrams of erythromycin were dissolved in 50.0 mL water 
and 5.0 mL of this solution was made up to 50.0 mL with blank urine. 
Appropriate dilutions of this stock solution were then made. The same 
internal standard solution was used as previously described for the 
analysis of serum samples (Section 3.3.1.1). 
3.4.1.2 Chromatographic Conditions 
These were identical to those in section 3.3.1.2 except that the 
spectrum-filter was not used i.e. Kratos detector 0.01 AUFS. 
3.4.1 . 3 Extraction Procedure 
One millilitre of urine was mixed with 500 ~L of the internal standard 
solution and 1.0 mL of acetonitrile. After centrifugation for 5 min at 
1 600xg the supernatant was transferred to a culture tube containing 
8.0 mL water. The samples were then extracted as for serum samples 
(Section 3.3.1.3). Between 1.0 and 5.0 ~L were injected onto the 
column. 
94 
3.4.1.4 Calibration Curve 
A calibration curve was constructed as described for the analysis of 
erythromycin in serum (Section 3.3.1.4). Concentrations ranged from 
5.00 to 50.00 ~g/mL. 
3.4.1.5 Precision 
Within-run precision was assessed by extracting six spiked urine 
samples each at the upper and lower limits of the concentration ranges 
studied (5.00 and 50.00 ~g/mL). 
3.4.1.6 Extraction Efficiency 
The analytical recovery of erythromycin in urine was assessed as for 
serum samples (Section 3.3.1.6), except that four concentrations of 
urine samples were analysed. 
3.4.2 Results and Discussion 
3.4.2.1 Linearity and Ca libration Curve 
Linearity was established for the range of concentrations studied (5.00 
to 50.00 ~g/mL). The curve had a slope of 0.0127, a y-intercept of 
0.0686 with a correlation coefficient of 0.9997. The calibration curve 
for erythromycin in urine is shown in Fig. 3.11. 
Initial studies using 0.5 mL urine for samples containing greater than 
30.00 ~g/mL erythromycin showed that the linearity at these higher 
concentrations was improved when 1.0 mL of urine was used throughout. 
A calibration curve using 1.0 mL samples in the concentration range 
7.50 to 30.00 ~g/mL had a correlation coefficient of 0.9997, whereas 
the same calibration curve using 0.5 mL of the 30.00 ~g/mL sample had a 
correlation coefficient of 0.9962. It was therefore decided to use 
1.0 mL samples throughout the study. 
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Chromatograms of a blank urine extract and a urine extract containing 
erythromycin and internal standard are depicted in Fig. 3.12. 
The retention time for erythromycin was 6.2 min and that of the 
internal standard 4.2 min. 
3.4.2.2 Precision 
Initial precision studies, performed with the internal standard being 
added in the acetonitrile used to precipitate the urine proteins, 
resulted in poor results. Table 3.5 shows the results of duplicate 
injections, of five identical spiked urine sample extracts, prepared 
with the internal standard being added as above. The within-run 
precision was poor, with a relative standard deviation of 16.8%. 
Duplicate injections of the same samples yielded almost identical 
results, indicating that the chromatography was not the cause of the 
poor precision. 
TABLE 3.5 Inter-sample and within- run precision on five urine samples 
(10.00 ~g/mL) with the internal standard being added in 0.5 mL 
acetonitrile 
PEAK HE IGHT RATIOS 
ERYTHROMYCIN/INTERNAL STANOARD 
SAMPLE 1ST INJECTION 2ND INJECTION AVERAGE 
0.80 0.80 0.80 
MEAN RATIO = 0.89 
(n=5) 
2 0.95 1.01 0.98 
SO 0.15 
3 1.10 1.10 1.10 RSO 16.8% 
4 0.78 0.82 0 .80 
5 0.74 0.75 0.75 
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This was subsequently established as being due to variations in the 
volume of internal standard added by the following experiment. 
Sufficient internal standard was added to 3.0 mL of urine, after which 
the samples were then separated into three equal aliquots and extracted 
as described. The relative standard deviation for these samples was 
only 1.2%. This effect may be due to either evaporation of the volatile 
acetonitrile during sample preparation, or due to a varying wetting 
phenomenon between the plastic tip and the solvent. 
The internal standard was then added as an aqueous solution (0.5 mL) 
prior to addition of the acetonitrile. This resulted in a dramatic 
increase in precision, 
4.0% at 5.00 ~g/mL and 
with the relative standard deviations being 
1.50% at 50.00 ~g/mL (Table 3.6), which was 
well within the accepted limits for drug determinations. 
3.4.2.3 Extraction Efficiency 
Table 3.7 shows the analytical recoveries of erythromycin in urine. The 
mean recovery of 79.5%, may be adjusted by 10-15% as discussed 
previously. This value corresponds well with the value obtained for the 
recovery of serum samples (82.4%). 
3.4.2.4 Sensitivity and Detection Limits 
Using 1.0 mL urine samples, the minimum detectable limit for 
erythromycin in urine under the above conditions was 1.00 ~g/mL. In 
view of the accessibility of large volumes of urine samples, this limit 
could be increased by the use of larger sample aliquots. 
3.4.2.5 Stability of Samples on Storage 
Spiked urine samples were found to be unstable when stored at 4°C for 
one week, but were found to be relatively stable after two weeks when 
stored at -10°C (Table 3.8-A-8). Extracted urine samples which had been 
reconstituted for injection, were found to have degraded after three 
days, even when stored at 4°C (Table 3.8-C). Samples extracted and 
taken to dryness, but not reconstituted, were relatively stable for one 
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FIGURE 3.11 Calibration curve of erythromycin in urine 
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TABLE 3.6 With in-run precision study on ur ine assay . 
SPIKED CONCENTRATION MEASURED l.g /mL) 
CONC 
SAMPLE NUMBER 
l.g/mL) 2 3 4 5 6 MEAN ISO) R.S.O. 
5.00 5.01 5.16 5. 25 5.22 4.71 4.95 5.05 10.20) 4.0% 
50.00 47.50 48.30 48.91 48.70 49.50 48.00 48.48 10.70) 1.5% 
TABLE 3.7 Analyti ca l recoveries of erythromycin from urine . 
URINE % RECOVERY 
CONC 
SAMPLE NUMBER 
l.g/mL) 2 3 Mean ISO) R.5.0. 
5.00 85.0 80 .0 85.0 83.3 12 .9) 3. 5% 
10.00 77 .5 82.5 82.5 80.8 12.9) 3.6% 
20.00 75 .0 75.0 75.0 75.0 0% 
50.00 76 .0 80 .0 80 .0 78.7 12.3) 2.9% 
Mean Pe rcentage recovery (n=12 ) 79.5 13.7) 4.7% 
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FIGURE 3.12 Chromatogram of (A) a blank urine extract (1.0 mL) and 
(B) a urine extract (1.0 mL) containing 
oleandomycin (1) and erythromycin (2) 
COLUMN : Novapak 
MOBILE PHASE: 0.05 M phosphate buffer/acetonitrile (70/30) pH 7.00 
INJECTION VOLUME: 3 ~L 
ERYTHROMYCIN CONCENTRATION : 5.00~g/mL 
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week at 4°C, whilst signs of degradation were evident after the second 
week (Table 3.8-D ). 
Extracted urine samples stored dry on the extraction columns prior to 
elution, also showed some evidence of degradation when analysed after 
storage for one week at 4°C (Table 3.8-E ). 
TABLE 3.8 Stability of urine samples 
SAMPLE STORAGE TIME OF ERYTHROMYCIN MEAN ERYTH ROMYC IN 
CONDITIONS STORAGE CONCENTRATION CONCENTRATION 
BEFORE STORAGE AFTER STORAGE 
.9/mL .9/mL (n 0 3) 
A 
URI NE SAMP LES 4'C 1 \IEEK 5.0 3. 5 
20 .0 14.5 
B 
UR INE SAMPLE - lOoe 1 WEEK 5.0 4.9 
50.0 24 .9 
2 WEEKS 5.0 5.0 
25 .0 22 .5 
50.0 45.0 
C 
UR INE EXTRACTS, 4' C 3 DAYS 5.0 3.8 
RECONST IT UTEO 10 .0 7. 7 
FOR INJECTION 50.0 38 . 2 
0 
DR I NE EXTRACTS, 4'C 1 WEEK 5.0 4.7 
PRI OR TO 50 .0 48. 5 
RECONST ITUT ION 
2 WEEKS 5.0 4. 0 
50 .0 42 .0 
E 
URINE EXTRACTS , 4'C 1 WEE K 5.0 4.2 
STORED ON 50.0 42.0 
EXTRACTION 
COLUMN 
2 WEEKS 5.0 4.0 
50 .0 30.0 
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FIGURE 3.13 Chromatogram of a urine sample (1.0 mL) containing 
erythromycin (20.00 ~g/mL) stored at 4°C for one week. 
1) oleandomycin 
2) erythromycin 
3) degradation product - possibly anhydroerythromycin 
4) degradation product 
COLUMN : Novapak 
MOBILE PHASE: 0.05 M phosphate buffer/acetonitrile (70/30) pH 7.00 
INJECTION VOLUME : 3 ~L 
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All the samples which were presumed to have degraded on storage, had 
small peaks of a similar retention to anhydroerythromycin (Fig.3.13). 
Due to the inability of the U.V. detection method to adequately detect 
this acid degradation product, the amount of this compound present 
could not be quantified. This would however be possible by performing 
these studies using electrochemical detection, as discussed in 
Chapter 4, which would lead to a better understanding of the stabi lity 
of erythromycin in biological fluids. 
3.5 CLINICAL STUDY 
3.5.1 Experimental 
A pilot trial using one volunteer was conducted to check the 
effectiveness of the analytical method to measure serum and urine 
concentrations of erythromycin base and any possible metabolites or 
degradation products after the oral administration of a commercially 
available erythromycin stearate formulation (ERYTHROCIN 500 - Abbott 
Laboratori es). 
The patient received one film coated tablet, containing 500 mg 
erythromycin stearate after an overnight fast, accompanied by 250 mL 
water immediately followed by a light breakfast. Blood samples were 
drawn at 0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, B, 10 and 12 hr after 
ingestion of the medication. The serum was separated by centrifugation 
and frozen until analyzed . Urine samples were collected during the time 
intervals 0-2, 2-4, 4-6, 6-8, 8-12 and 12-24 hrs and representative 
samples were frozen until analyzed. 
3.5.2 Results and Discussion 
The HPLC method was extremely suitable for the determination of 
erythromycin in serum and urine following a single 500 mg oral dose . 
The serum concentration-time profile and cumulative urinary excretion 
profile from this study are depicted in Figs. 3.14 and 3.15 
respectively. No metabolites or degradation products were detected 
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FIGURE 3.14 Serum erythromyci n concentration-time profile of a 
human volunteer after administration of a single 
500 mg erythromycin stearate tablet. 
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FIGURE 3.15 Cumulative urinary erythromycin concentration- time 
profile of a human volunteer after administration 
of a single 500 mg erythromycin stearate tablet. 
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using U.V. detection, however, subsequent analysis of the urine samples 
from this study (stored at -10°C) indicated the presence of high 
concentrations of anhydroerythromycin. It was not known whether this 
product had formed through the degradation of erythromycin on storage, 
or whether it had indeed been present on collection of the sample. 
Further studies in our laboratory have indicated the presence of 
anhydroerythromycin in urine samples on collection, after oral 
administration of the same dosage form as above. No attempt has been 
made to quantify the amount of this product excreted via this route. 
The presence of anhydroerythromycin and an unknown product in serum and 
urine of dogs after oral administration of erythromycin has been 
reported using HPLC with electrochemical detection (9) . A compound of 
similar retention characteristics to the unknown product reported in 
the previous study discussed (9), was reported in serum of humans after 
oral administration of a suspension of erythromycin (99) (Section 3.1). 
In addition, des-N-methylerythromycin has been detected in the biliary 
fluid, intestinal contents and urine of rats (87), and erythralosamine 
in human serum (152). No studies have been reported to date, in which 
the ratios of these metabolites/degradation products in biolog i cal 
fluids has been studied. 
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CHAPTER FOUR 
HPLC OF ERYTHROMYCIN WITH ELECTROCHEMICAL DETECTION 
4.1 INTRODUCTION 
The first practical electrochemical detector for liquid chromatography 
was developed for the purpose of monitoring catecholamines in brain 
tissue (159). Following this initial publication, high performance 
liquid chromatography with electrochemical detection (HPLC - EC) has 
become very popular for the determination of trace amounts of easily 
oxidizable or reducable substances, mainly due to three distinct 
advantages: sensitivity, selectivity and economy (160). 
Electrochemical detection results from a current-producing reaction at 
an electrode surface (160). This can either be an oxidation or a 
reduction reaction. The general oxidation reaction for a compound XH Z 
can be depicted as follows. 
XH Z -:::. X + 2H+ + 2e (Equation 4) 
This reaction takes place in a low volume flow -through cell which is 
connected to the column outlet (Fig.4.1). The working electrode (WE) 
is the electrode at which the reaction takes place and is set at a 
constant voltage, called the electrode potential, which is compared to 
a stable reference electrode (RE). The current resulting from the 
reaction at the WE, which is proportiona l to the amount of the eluting 
compound present (160) is measured by the auxi liary electrode (AE) . The 
sensitivity (detector current) of the instrument is governed by the 
amplification of this signal. 
All cells operating in this fash ion, with the WE held at a constant 
potential, are said to be amperometric. The WE typically causing the 
oxidation of 1-10% of the passing analyte. When this percentage 
reaches 100%, the electrode i s said to be coulometric (160). The 
reaction at the WE is dependent on the electrochemical properties of 
the compounds of interest at the specific electrode surface utilized, in 
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FIGURE 4.1 Single electrode, amperometric electrochemical detector 
flow cell (Metrohm) 
Working Electrode 
Reference Electrode Auxiliary Electrode 
~ Inlet 
the mobile phase required for their separation (159). 
As a general rule, electrochemical detection is not possible in normal 
phase chromatography due to the totally non-aqueous solvent systems 
used, whilst in reverse phase and ion-exchange chromatography the 
mobile phases which consist of small proportions of polar organic 
solvents mixed with aqueous phases containing dissolved salts, provide 
a suitable medium for electrochemical reactions (161). 
In HPLC - EC the oxidative mode of detection is most often used (160). 
The presence of oxygen in the mobile phase and the sample, has proved 
to be the major deterrent for utilization of HPLC-EC in the 
mode (162). In this study, only the oxidative mode was used. 
the general discussion of electrochemical detection is 
applicable to the reductive mode. 
reductive 
However, 
equally 
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The choice of the optimum electrode potential for a compound is made 
from a voltammogram. This is a plot of current generated versus 
electrode potential applied under the conditions of analysis (163). 
Cyclic voltammetry, in which a constant supply of analyte is scanned 
over a range of electrode potentials and the resulting current recorded 
may be used, but in HPLC-EC, hydrodynamic voltammograms are more easily 
prepared (163). In the preparation of these voltammograms, equivalent 
amounts of analyte are successively injected into the chromatographic 
system at varying electrode potentials. The resulting response, 
measured by peak height or area, is then plotted versus the 
electrode potential applied. Hydrodynamic voltammograms of 
erythromycin and two metabolites/degradation products at glassy 
carbon and porous graphite electrodes are depicted in Fig.4.3. The 
electrode potential which results in half of the maximum oxidation, is 
called the half-wave potential and is used to compare the potentials at 
which different compou nds are oxidized (163). 
The optimum electrode potential is generally chosen as the lowest 
potential necessary to provide the desired sensitivity. This results 
in low background currents and hence a reduction in detector noise with 
a concomitant increase in selectivity and decrease in the rate of 
electrode contamination which is most evident at high operating 
potentials (160,164). Carbon electrodes are generally preferred over 
metallic electrodes such as gold or platinum due to their versatility, 
chemical inertness and large potential ranges of operation (typica lly 
-1.0 to +1.0 V) (165). In amperometric cells, glassy carbon 
electrodes , as used in the amperometric cell described in Fig.4.1, 
are most commonly employed whilst for special applications, dual glassy 
carbon electrode cells in various orientations have also been designed 
(166). In a cell which is operated on the wall-jet principle, the WE 
is not merely placed in the flow path of the cell but is continuously 
impinged upon by a stream of eluent, resulting in maximum contact 
between the electrode surface and reacting compounds (167). 
Coulometric electrodes (Fig.4.2) are most commonly made of porous 
graphite or carbon composites with inert plastics through which the 
eluent flows, although glassy carbon and carbon paste beds have been 
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used (163). The large surface area avai lable allows the reaction of 
100% of the passing analyte, resulting in the maximum possible signal. 
This signal, however, does not result in the most favourable signal -to-
nOise ratios due to associated increases in background currents (160). 
The main advantages of coulometric electrodes are their ability to 
maintain suitable operation with up to 95% of their surface area 
contaminated, good signal stability and exce llent screening 
efficiencies in dual electrode cells (168). The screening abilities 
of these electrodes are demonstrated by the operation of a dual porous 
graphite electrode coulometric cell, in the oxidative screen mode 
(Fig. 4.2). In this operation mode, the upstream electrode is set at 
an electrode potential just lower than the ris ing part of the 
voltammogram prepared for the compound of interest. All easily oxidized 
compounds and sample constituents are oxidized at th is electrode and 
are thus not detected at the downstream electrode which is set at the 
optimum electrode potential for the detect ion of the compounds of 
interest. If an amperometric electrode is used as the upstream 
electrode the maximum screening efficiency can only be 10% . 
FIGURE 4.2 Dual electrode , coulometric electrochemical detector flow 
cell (Coulochem) 
Upstream Electrode Downstream Electrode 
Inlet ~ ~ Outlet 
•• 
Ce ll Body with Heat Sink and Heater 
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When operating potentials are high (> + 0.8 V) a guard cell can be 
incorporated into the HPLC system between the solvent delivery system 
and the injector (115). This cell consists of a single coulometric 
electrode which pre-oxidizes any electroactive impurities in the mobile 
phase prior to chromatography, resulting in decreased baseline drift 
due to constant background currents (163). At these high operating 
potentials, electrochemical detectors are extremely sensitive to pump 
pulsations and contamination due to graphite impregnated teflon 
material used in many automatic samplers, pumps and manual injection 
systems (169). These effects can be greatly reduced by passivation of 
all equipment prior to use, which norma lly involves a strong acid wash, 
or the use of ethylenediamine tetracetic acid to remove electroactive 
compounds from the wetted surfaces of all chromatographic components 
(163). Compounds which must be analysed at these high potentials suffer 
a loss in detection limits due to high detector noise (160). For 
maximum sensitivity and decreased background currents only the 
highest grade chromatography solvents should be used, but even then, 
their electrochemical purity can not be guaranteed, as they are 
prepared predominantly for use with optical detectors (163) 
particularly at low U.V. wavelengths. 
The variation in detector response, either due to reference voltage 
shifts or electrode contamination (161), is still a major problem in 
HPLC-EC, although recent advances in electrode design (170) and 
electrode stabilization procedures, have limited these effects 
considerably (99). 
4.2 EXPERIMENTAL 
4.2.1 Sample Preparation 
Serum samples containing 1.00 ~g/mL and urine containing 5.00 ~g/mL 
erythromycin were prepared as in section 3.3.1.1. An aqueous mixture 
of erythromycin, anhydroerythromycin and des-N-methylerythromycin was 
prepared as follows: 
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Five milligrams of each of these compounds were dissolved in 10.0 mL 
water and 1.0 mL aliquots of each solution were added to an injection 
vial. A three microlitre injection of this mixture represented an on-
column load of 0.50 ~g of each compound. 
4.2.2 Chromatographic Conditions 
HPLC System 
Column 
Mobile phase 
Flow rate 
Pressure 
Temperature 
Detection 
Sensitivity 
Recorder input 
4.2.3 Instrumentation 
As in Section 2.3.2 
Novapak 
0.05 M phosphate buffer/acetonitrile 
(70/30), pH 7.00 
1.0 mL/min 
1500 psi 
35°C 
U.V. 200 nm (Kratos Detector) 
Electrochemical 
0,01 AUFS (U.V.) 
10 mV 
4.2.3.1 Amperometric Electrochemical Detector 
A Metrohm 656 electrochemical detector was used in combination with a 
Metrohm Model 641 VA current/voltage measuring device. The standard 
wall-jet cell consisted of a glassy carbon working electrode, a glassy 
carbon auxiliary electrode and a silver/silver chloride reference 
electrode. This detector cell, which is depicted in Fig.4.1, was 
placed in line after the U.V. detector. 
4.2.3.2 Coulometric Electrochemical Detector 
An Environmental Sciences Associates Model 5100A Coulochem dual 
electrode electrochemical detector fitted with a standard model 5011 
analytical cell was used. This cell consisted of two high surface area 
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porous graphite coulometric electrodes and was operated either as a 
conventional single electrode cell or in the screen mode using both 
electrodes. The detector was placed in line after the U.V. detector, 
and the cell is depicted in Fig.4.2. During the initial studies, a 
model S020 guard cell operated at a potential of + 1.0 V was used. 
4.2.4 Construction of Voltammograms 
Hydrodynamic voltammograms for both electrochemical detectors were 
constructed as follows: 
The detector was set at a low electrode potential (+ O.S V) and the 
chromatographic system left to stabilize under normal operating 
conditions. Three microlitres of a mixture of erythromycin, 
anhydroerythromycin and des-N-methylerythromycin were injected onto the 
column. 
microamps 
repeated 
The peak heights of each compound were converted to a value in 
by simple proportion. This procedure was continuously 
after the electrode potential had been increased by O.OS V 
increments each time, with sufficient time being allowed for electrode 
stabi I ization. 
4.2.S Extraction Procedures 
4.2.S.1 Solid Phase Extraction of Serum and Urine 
One millilitre samples of urine and 2.0 mL samples of serum were 
~ 
extracted as previously described (Section 3.3.1.3 and 3.4.1.3). Five 
microlitre aliquots were injected onto the column. 
4.2.S.2 Liquid - Liquid Extraction of Serum 
The extraction method of Chen and Chiou (9) was used, which was similar 
to that reported by Duthu (99), for the extraction of erythromycin 
from serum for HPLC-EC analysis. 
One millilitre of serum and 100 ~L of saturated sodium carbonate were 
vortexed for 1S sec. Two millilitres of ether were added, the tube 
stoppered, vortexed 
1 600xg. The ether 
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for min and centrifuged for 5 min at 
layer was then transferred to a 2 mL tapered 
collection tube and evaporated to dryness under vacuum in a rotary 
vacuum centrifuge. The residue was reconstituted with 50.0 ~L of 
mobile phase and centrifuged. Approximately thirty microlitres were 
transferred to a WISP limited volume insert of which 10.0-20.0 ~L were 
injected onto the column. 
4.2.5.3 Liquid - Liquid extraction of Urine 
The extraction method of Chen and Chiou (9) for the extraction of 
erythromycin from urine for HPLC-EC was used. 
Two hundred microlitres of acetonitrile were added to 100 ~L urine. 
The tube was then vortexed for 30 sec and centrifuged at 1 600xg 
for 5 min. One hundred microlitres were transferred to a WISP limited 
volume insert of which 10.0-20.0 ~L were injected onto the column. 
4.3 RESULTS AND DISCUSSION 
4.3.1 Select ion of Electrode Potentials 
Erythromycin has been analyzed by HPLC-EC at ·electrode potentials above 
+0.8 V (9,99). Under the condit ions of this study, similar electrode 
potentials were necessary (Fig. 4.3). From the voltammograms prepared 
it can be seen that erythromycin has a higher half-wave potential 
(+1.15 V) at the glassy carbon electrode than at a porous graphite 
elect rode (+0.7 V). 
For the Metrohm detector, an electrode potential of +1.15 V was found 
to yield the best compromise between detector response and baseline 
noise. For the Coulochem detector operated in the single electrode 
mode +0.90 V was chosen as the optimum electrode potentia l whilst 
in the oxidative screen mode, electrode potentials of +0.70 V for 
the upstream electrode and +0.90 V for the downstream electrode 
were selected. These potentials were the best compromise between 
efficient screening and detector sensitivity. 
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FIGURE 4.3 Hydrodynamic Yoltammograms of erythromycin, 
methylerythromycin and anhydroerythromycin using: 
(A) Glassy carbon e lectrode (Metrohm) 
(8) Porous graphite electrode (Coulochem) 
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From Fig.4.3 it can be seen that both des-N-methylerythromycin and 
anhydroerythromycin have higher half-wave potentials than erythromycin. 
At the electrode potentials chosen for the analysis of erythromycin. 
des-N-methylerythromycin was not easily detectable whereas 
anhydroerythromycin was. 
The inability to detect des-N-methylerythromycin by HPLC-EC has 
previously been reported by Duthu (99). Chen and Chiou (9). however. 
stated that this metabolite could be detected under their operating 
conditions (oxidative screen mode at +0.70 V for the upstream 
electrode and +0.90 V for the downstream electrode) although no 
chromatograms were shown. nor was the sensitivity of detection given. 
An electrochemical pretreatment procedure for glassy carbon electrodes 
has been reported by Ravichandran and Baldwin (171). This procedure 
involves sequential application of brief positive and negative pulses 
to the polished electrode which lowers the required electrode potential 
compared to that needed at conventional untreat ed gla ssy carbon 
electrodes. This procedure may be of use in this study as increased 
selectivity is obtained due to the lower electrode potentials used. 
with the added advantage of increased sensitivity. 
4.3.2 Sensitivity of Electrochemical Detection: Comparison to U.V. 
Detection at 200 nm 
When operated at the electrode potentials discussed in section 4.3.1. 
the Metrohm amperometric detector was approximately five t imes more 
sensitive 
(Fig.4.5). 
than the U.V. detector when monitoring erythromycin 
The detector current (sensitivity) when set at 100 nA 
provided the best compromise between sensitivity and baseline noise or 
drift. 
The Coulochem detector operated in the single electrode mode at 
+0.90 V was found to generate high background currents allowing a 
maximum sensitivity setting of 1 x 30. This resulted in a smooth 
baseline. but decreased the sensitivity of the detector considerably to 
about twice that of the U. V. detector (Fig. 4.5). 
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U.V. DETECTOR 200 nm 0,01 AUFS 
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COULOCHEM ELECTROCH EMICAL DETECTOR 
SINGLE ELECTRODE 
SENSITIVITY SETTING 10 x 3 
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METROHM ELECTROCHEMICAL DETECTOR 
SINGLE ELECTRODE 
DETECTOR CURRENT 100 nA 
FIGURE 4.4 Blank serum extracts (2.0 mL) extracted using the method of 
Chen and Chiou (9), monitored by four different 
detection systems. (1) Expected retention of erythromycin 
(2) Unidentified peak 
COLUMN : Novapak 
MOBILE PHASE: 0.05 M phosphate buffer/acetonitrile (70/30), pH 7.00 
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The Coulochem detector operated in the oxidative screen mode as 
discussed in Section 4.3.1, generated far lower background currents, 
enabling the sensitivity setting to be increased to 10 x 10 or even 
15 x 10. This resulted in an approximate ten fold increase in 
sensitivity over the U.V. detector (Fig. 4.7). 
4.3.3 Liquid - Liquid extraction of Serum and Urine 
Chromatograms of blank serum samples (2.0 mL) extracted using the 
liquid-liquid procedure described (9) and monitored by electrochemical 
and U.V. detection are depicted in Fig 4.4. From these chromatograms 
it can be seen, that the high levels of interfering compounds would 
inhibit the quantification of erythromycin, irrespective of the 
detection method. Chen and Chiou (9) overcame this problem by 
increasing the retention of erythromycin to 9.6 min in order to 
separate the drug from interfering compounds. Similar result s were 
obtained for the analysi s of ur ine samples extracted by thi s procedure. 
4.3.4 Solid Phase extraction of Serum and Urine 
Injection of serum or urine samples extracted by the solid phase 
technique resulted in chromatograms similar to those obtained when 
using U.V. detection at 200 nm but with increased sensitivity, as 
discussed in Section 4.3.2. Chromatograms of solid phase serum 
extracts containing 1.00 ~g/mL erythromycin monitored by U.V., 
amperometric electrochemical detection at a single glassy carbon 
electrode and coulometric detection at a single porous graphite 
electrode, are depicted in Fig. 4.5. The lack of interference from co-
eluting serum components is shown in all three chromatograms, allowing 
the unhindered quantification of erythromycin. The solid phase 
extraction method has been shown to not only be suitable for U.V. 
detection at low wavelengths, but also for electrochemical detection 
at high electrode potenti als using even single glassy carbon 
electrode amperometric cells. 
The solid phase extraction system used with the Coulochem 
electrochemical detector resulted in chromatograms relatively f ree from 
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co-eluting serum and urine components with an increased sensitivity for 
erythromycin over the U.V. detection method. 
For the analysis of urine samples, in which erythromycin concentrations 
are seldom lower than 1.00~g/mL the Coulochem detector was operated at 
low sensitivity settings (15 x 1 or 30 x 1). Under these conditions, 
comparable sensitivities for erythromycin were obtained for both the 
U.V. and electrochemical detectors. Chromatograms from the 
electrochemical detector contained far less interference from co-
eluting urine components than those from the U.V. detector (Fig.4.6). 
For the analysis of erythromycin in serum using the solid phase 
extraction system the increased sensitivity of the Coulochem 
electrochemical detector proved most useful. During these analyses the 
sensit ivity of this detector was increased to the maximum setti ng which 
still resulted in a smooth baseline (10 x 10 or 15 x 10). An 
approximate 
U.V. method 
increase in 
(Fig.4.7). 
10 fold increase in sensitivity for erythromycin over the 
was obtained under these conditions without any dramatic 
the interference from co-eluting serum components 
4.3.5 Detection of Metabolites/Degradat ion Products 
As previously discussed, anhydroerythromycin was readily detectable by 
electrochemical detection at the electrode potentials used for the 
analysis of erythromycin, whilst des-N-methylerythromycin was not. The 
reverse was true for these compounds when using U.V. detection. This is 
clearly depicted in Fig.4.8. 
4.3.6 Comparison of Electrochemical and U.V. Detection 
In the HPLC analysis of erythromycin, electrochemical detection was 
definitely more sens iti ve than U.V. detection. The liquid - liquid 
extractions used by other workers in this field (9,99) could not be 
successfully adapted to the chromatographic conditions of this study, 
irrespective of the detection method used. The solid phase 
extraction procedure developed for the U.V. assay, however, has been 
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shown to be entirely suitable when coupled with electrochemical 
detection. The use of simple single electrode electrochemical 
detectors is now possible, unlike previously reported (9,99), due to 
the effectiveness of this novel extraction procedure. 
The utility of the U.V. detector to detect des-N-methylerythromycin 
and not anhydroerythromycin with the reverse being true for 
electrochemical detection, shows the potential advantages of using 
both detection methods in combination, for future pharmacokinetic and 
metabolic studies. 
Despite adherence to prescribed procedures and precautions necessary 
for optimal use of electrochemical detectors (9,99,163), changes 
in day-to-day response were clearly evident, which is in distinct 
contrast to the stable and reproducible response associated with U.V. 
detectors used in HPLC. The stability of the electrochemical signal 
over a lengthy period of analyses and the linearity of response over a 
wide concentration range using the conditions of this assay, have not 
yet been shown. 
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SUMt·1ARY AND PROPOSED AREAS OF FUTURE RESEARCH 
The HPLC method described using U.V. detection has been shown to be 
specific, precise and sufficiently sensitive to monitor the 
concentrations of erythromycin in serum and urine after the 
administration of oral dosage forms. 
The solid phase extraction system developed for the analysis of 
erythromycin in serum and urine using low wavelength U.V. detection has 
also been shown to be applicable when using a simple and inexpensive 
electrochemical detector. The combination of the extraction procedure 
together with a sophisticated dual-electrode electrochemical detector 
operated in the oxidative screen mode resulted in cleaner sample 
extracts than those obtained by other workers (9,99) using this form of 
detection and also resulted in increased sensitivities over the U.V. 
detection method described .. 
The utility of the HPLC-UV method to detect des-N-methylerythromycin 
should provide useful informat ion relating to both the rate of 
formation and rate of excretion of this metabolite, particularly if 
this method could be adapted to the analysis of biliary fluids. 
The reported detection of anhydroerythromycin in serum and urine of 
dogs after oral admin istration of erythromycin (9) and the results of 
preliminary studies in our laboratory in which quantifiable 
concentrations of this degradation product were found in urine after 
the administration of an oral erythromycin stearate formulation to 
humans (using HPLC-EC), should yield valuable data relating to the 
absorption/transformation of erythromycin in man. 
A further analytical method may be developed for the analysis of the 
esters of erythromycin in serum and urine which would enable the 
comparison to be made between the concentrations of active erythromycin 
base and inactive ester during pharmacokinetic and comparative bio-
availability studies. 
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As previously discussed in section 1.4 numerous studies have been 
performed to elucidate the pharmacokinetics of erythromycin in man 
after both i.v. and oral administration. There is still much 
disagreement over many aspects of these studies. However, the basic 
pharmacokinetic parameters reported are largely similar. All these 
studies have been performed using microbiological assay techniques 
which are only able to quantify the concentrations of 
microbiologically active erythromycin present and are therefore unable 
to distinguish between concentrations of erythromycin and any inactive 
or re latively inactive metabolites and/or degradation products present 
in serum and urine. The present HPLC method described which is capable 
of selective quantification of these compounds, should provide a 
powerful analytical tool for the study of various aspects of the 
absorption and disposition characteristics of erythromycin in man. 
Various aspects of previous studies may now be re-examined using this 
ana lytical procedure, which should lead to a more comprehensive 
characterization of the pharmacokinetics of th is antibiotic . These 
areas of future research include: 
1) Re-investigation of the pharmacokinetics of erythromycin after i.v. 
dosage and the reported evidence of non-linear elimination of the 
drug. 
2) Re-investigation of the pharmacokinetics of erythromycin after 
single and multiple dose oral studies with particular attention to 
differences in the pharmacokinetics of the various derivatives of 
erythromycin. 
3) Studies on the comparative bio-availability of erythromycin and its 
derivatives by comparison of serum and urine concentrations of both 
active drug and inactive ester as well as any metabolites/ 
degradation products present. 
4) Re-investigation of the reported differences between the bio-
availability of erythromycin after single and multiple doses, with 
particular attention being paid to the concentrat ions of any 
metabolites/degradation products present after the two dosing 
schedules. 
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5) Studies on intra-subject variations in erythromycin 
pharmacokinetics after oral administration of single and multiple 
doses. 
6) Studies of the effects of possible entero-hepatic recycling and 
active secretion of the drug into the jejunum. 
7) Re-investigation of the work of Chelvan et a2.(89) on the biliary 
excretion of erythromycin, with the added advantage of being able 
to quantify the amount of des-N-methylerythromycin excreted via 
this route. 
8) Studies on the effect of concurrent food and water administration 
the bio-availability of erythromycin and its derivatives using the 
concentrations of anhydroerythromycin in serum and/or urine, as an 
indicator of the extent of gastric degradation of the drug. 
9) Studies on the metabolism of erythromycin in tissue cultures of 
liver and gut-mucosal cells, as well as the metabolism due to 
commensal gut flora. 
10) Further studies on the effects of erythromycin on theophylline 
kinetics and vice ver~a, with particular attention to any possible 
changes in the ratios of metabolites in serum and/or urine, 
occuring after co-administration of the two drugs. 
The HPLC method described is ideally suited for further studies on the 
stability of erythromycin in serum and urine as well as in vitro 
studies on the rates of degradation of erythromycin and its derivatives 
in both acidic and basic media. Studies on the stability of 
erythromycin during the incubation period associated with 
microbiological assay methods are also envisaged. 
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